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Abstract
Business leaders who fail to implement innovative technology solutions in their
companies face economic distress in these organizations. Guided by the task technology
fit model as the conceptual framework, the purpose of this qualitative single case study
was to explore strategies used by pharmacovigilance (PV) systems leaders to implement
innovative technology solutions. The participants were 4 PV systems managers working
in a pharmaceutical company in the Boston area of Massachusetts, United States, who
used successful strategies to implement innovative technology solutions to automate
adverse events case processing. Data were collected using semistructured interviews and
company documents. The collected data were analyzed using Yin’s 5-step data analysis,
which included compiling, disassembling, reassembling, interpreting data, and
concluding the findings. Three key themes emerged: automation solution selection and
implementation strategies, business operation model changes, and communication and
training strategies. The key recommendation is for PV leaders to implement automation
solutions and redirect the savings from PV operations in terms of cost and workforce
tasks toward investing in the actual PV tasks such as benefit-risk assessments of products.
The implications for positive social change include the potential to identify strategies to
improve patient outcomes and assist in making pharmaceutical medicines more
efficacious and safer for human use in reducing unnecessary deaths.
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Section 1: Foundation of the Study
The goal of pharmacovigilance (PV) is to protect patients from unnecessary harm.
When a medicine is marketed, the identification and monitoring of adverse events (AEs)
and reactions is a part of a post-marketing safety surveillance program as required by
federal regulations (Kothari, Shah, & Patel, 2018; Tan et al., 2016). Health regulatory
agencies have regulations to ensure that drug products are safe for human consumption.
Companies that are licensed marketing authorization holders are required by regulation to
perform active drug safety surveillance and monitor the safety profiles of the products
during the entire marketing lifecycle (Basile, Yahi, & Tatonetti, 2019). Companies use
safety databases and reporting software to process and report AEs to health authorities
around the world (Lewis & McCullum, 2019). Companies can use innovative information
technology solutions based on artificial intelligence and robotics to detect, process, and
report AEs, thereby adopting automation (Beninger, 2018; Donzanti, 2018). Companies
can adopt an automation-enabled digital PV path for drug safety surveillance and redirect
the savings from PV operations toward investing in the actual PV tasks like benefit-risk
assessments of products, thereby making the products more efficacious and safer for
human use.
Background of the Problem
The safety of medicines is a global responsibility. A drug product or medicine
will gain marketing authorization after a regulatory agency conducts comprehensive
reviews of the drug product to evaluate the benefits and risks (Schurer, Bam, & de Kock,
2017). When the officials of the agency find a favorable benefit-risk balance, they
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approve the drug product to be marketed within the jurisdiction of the relevant agency
(Kothari et al., 2018). When the product is marketed and consumed by a large population,
adverse reactions or side effects may occur (Pitts, Louet, Moride, & Conti, 2016). When
a product is reported to have caused serious AEs, national authorities analyze the reports
of the product and weigh the risks and benefits. They then decide on a course of action,
which may include issuing an alert or, in extreme cases, taking the product off the market
(McNaughton, Huet, & Shakir, 2014).
The goal of PV is to protect patients from unnecessary harm. Unsafe healthcare
causes harm and leads to other forms of collateral damage such as loss of trust in the
system and loss of reputation and credibility in health services (World Health
Organization, 2017). The occurrence of AE is one of the top 10 causes of death and
disability across the world (World Health Organization, 2019a). Officials of the World
Health Organization reported that 134 million adverse events occur each year in
hospitals, contributing to 2.6 million deaths annually due to unsafe care (World Health
Organization, 2019c).
Biomedical informatics including artificial intelligence (AI) and robotics-based
solutions can accelerate efficiencies and can be used to identify and process AEs faster
and contribute to reduction of costs (Beninger, 2018; Donzanti, 2018). Despite multiple
successful experiments, not many managers in pharmaceutical companies have developed
and/or implemented innovative technology to realize the benefits.
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Problem Statement
Business leaders who fail to implement innovative technology solutions in their
companies face economic distress in these organizations (Bal & Erkan, 2019). Failure to
implement innovative technology solutions result in high pharmacovigilance (PV)
operational costs related to the 2.2 million adverse events (AEs) documented by the U.S.
Food & Drug Administration (2019) that could cost pharmaceutical companies $900
million for drug recalls (Hall, Stewart, Chang, & Freeman, 2016). The general business
problem is that PV systems managers may experience high operational costs for AE
detection and reporting leading to poor financial performance. The specific business
problem is that some PV systems managers in the pharmaceutical industry lack the
strategies to implement innovative technology solutions to automate AE case processing.
Purpose Statement
The purpose of this qualitative single case study was to explore the strategies that
PV systems managers in the pharmaceutical industry use to implement innovative
technology solutions to automate AE case processing. The target population consisted of
four PV systems managers working in a pharmaceutical company located in the Boston
area of Massachusetts, United States, who had used successful strategies to implement
innovative technology solutions to automate AE case processing. The implications for
positive social change include the potential to improve patient safety by identifying
successful strategies that PV systems managers can use or adapt to implement innovative
technology solutions to automate AE case processing.
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Nature of the Study
Qualitative studies are based on interpretive philosophy. Using an inductive
approach, researchers use a smaller sample of participants’ data to develop rich data and
thick descriptions through a variety of methods for data collection to identify patterns
associated with phenomena (Fusch, Fusch, & Ness, 2018; Saunders, Lewis, & Thornhill,
2015). In quantitative and mixed methods studies, researchers use quantitative measures
and inferential statistics to examine relationships among variables (Saunders et al., 2015).
Since not many company managers have implemented innovative technology like AI and
robotics-based solutions for PV (Beninger & Ibara, 2016), I focused on a select group of
managers who had successfully used strategies to implement innovative technology
solutions to automate AE case processing. Therefore, because of the need to use
qualitative data collection procedures like interviews and documentation reviews, a
qualitative method was more appropriate than quantitative or mixed methods.
Qualitative case studies are flexible in nature, focusing on a phenomenon, and

evolve over the course of the study (Yin, 2018). Using a case study strategy enables
researchers to perform in-depth inquiry into a topic to generate insights in a real-life context

experiences (Saunders et al., 2015; Yin, 2018). Using multiple case study design, researchers
can collect and analyze data to gather perspectives and identify patterns and themes
concerning a specific situation across multiple cases (Yin, 2018). Using ethnography and
phenomenological study designs, researchers focus on people, culture, and phenomena
(Saunders et al., 2015). Because I explored successful innovative technology implementation
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strategies used by PV systems managers in a pharmaceutical company, a single case study
design was more appropriate for this study than a phenomenological or ethnographic design.

Research Question
The primary research question for this study was: What strategies do PV systems
managers use to implement innovative technology solutions to automate AE case
processing?
Interview Questions
1. What strategies did you use to identify automation solutions for AE case
processing?
2. What strategies did you use for implementing the identified automation solution?
3. What, if any, kinds of operational changes did the automation solution require to
your PV business operations model?
4. What communication strategies were used to manage regulatory obligations and
employee’s expectations to enable employee’s adoption of the automation
solution?
5. What key difficulties did your organization face when implementing the
automation technology solution?
6. How did your organization overcome the key difficulties to implementing
automation technology solution?
7. How did your organization assess the implementation strategies’ effectiveness?
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8. What additional information can you add about the development and
implementation of the strategies your organization used for automating AE case
processing?
Conceptual Framework
The conceptual framework that I selected for my doctoral study was based on the
information systems theory’s task-technology fit (TTF) model. The TTF model focuses
on the degree to which systems characteristics match user task needs. Goodhue (1995)
proposed the TTF model to evaluate and measure success of information systems and
posited that a high task-technology fit will positively impact the performance. Goodhue
and Thompson (1995) further empirically tested the link between information technology
and individual performance and asserted that the utilization of technology and the
technology itself must be a good fit for the tasks it supports. TTF links the task
requirements, individual abilities, and the functionality of technology. More recent
researchers have improved the TTF model by incorporating additional characteristics and
constructs or by integrating other theories such as the appropriation theories (Park, 2019).
I compared the expected results from the TTF model with the actual results from my
study to understand the study’s findings.
Operational Definitions
Adverse events or reactions: Adverse events or reactions are unexpected harm
caused by the normal use of medication at the normal dosage (Karimi, Wang, MetkeJimenez, Gaire, & Paris, 2015).
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Adverse event reporting: Adverse event reporting refers to the activities that
marketing authorization holders perform to collect, and report AE cases reported by
patients as required by a 2012 PV legislation (Kothari et al., 2018).
Digitalization: Digitalization involves using digitized data to make decisions and
generate change (Gobble, 2018).
Healthcare information technology: Healthcare information technology is the
application of computers for the storage, retrieval, sharing, and use of health care
information, data, and knowledge for communication and decision making (Alotaibi &
Federico, 2017).
Pharmacovigilance: PV is studying the safety and effectiveness of drugs
including the activities relating to detection, assessment, understanding, and prevention
of the AE associated with the use of drugs (World Health Organization, 2019b).
Assumptions, Limitations, and Delimitations
Assumptions
Assumptions are unverified beliefs pertaining to a study (Locke, Spirduso, &
Silverman, 2014). I made the following assumptions in this study: (a) the participants
provided honest, truthful responses to the interview questions, (b) the participants had
relevant information and experiences, (c) the responses provided by the participants
assisted in understanding the strategies used to implement innovative technology
solutions to automate AE case processing, and (d) the strategies provided by the
participants improved efficiencies in processing AEs. Following the conclusion of my
interviews with the participants, I found all these assumptions to be true.
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Limitations
Limitations are potential weaknesses which are beyond the researcher’s control
(Singh, 2015). One of the limitations for this study was that the participants were
employed in one pharmaceutical company. Restricting the study population to one
company may limit the transferability of the methods used in my study for future
research. Another limitation was that the member checking was conducted by emails
since most of the follow-ups occurred during the actual interviews.
Delimitations
Delimitations are boundaries intentionally established to narrow the scope of a
study for the researcher (Holloway & Galvin, 2016). The scope of my study was limited
to participants from one pharmaceutical company. A purposeful sampling of four
participants who were associated with the AE case processing automation project was a
delimitation. Potential participants who did not work for the selected company, though
eligible, were not a part of this study.
Significance of the Study
PV is a study of the safety and effectiveness of drugs including the activities
relating to detection, assessment, understanding, and prevention of the AEs associated
with the use of drugs (Beninger & Ibara, 2016; World Health Organization, 2019b).
Processing of an AE is an expensive resource-intensive process, which includes high risk
of errors and operational inefficiencies (Ghosh et al., 2020). In 2019, the U.S. Food &
Drug Administration (2019) received 2.2 million AEs which is a 450% increase since
2009, which increased the derivative AE-related operational costs for pharmaceutical
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companies. Biomedical informatics including AI and robotics-based solutions can
accelerate efficiencies, identify and process AEs faster, and contribute to costs’ reduction
(Beninger, 2018; Donzanti, 2018). I explored the strategies that PV systems managers in
the pharmaceutical industry use to implement innovative technology solutions to
automate AE processing.
Contribution to Business Practice
Information technology (IT) offers a wide range of opportunities to organizations
for automating, informing, and transforming their businesses. The IT-driven approach
toward business process management enables business process innovation to align with
industry best practices and emerging IT trends (Rahimi, Moller, & Hvam, 2015).
Managers must build dynamic capabilities and learning in their organizational processes
(Čiutienė & Thattakath, 2014), which in combination with business model innovation
should result in higher value appropriation (Sorescu, 2017). PV technology systems can
be effective in detecting what may be otherwise invisible to the human eye, increasing
productivity, and more likely to identify important public health information within large
data bases (Lu, 2009). Data mining, machine learning, AI, and robotics could result in
new operating models for PV (Beninger & Ibara, 2016; Lai, 2017), improve efficiencies
and reduce PV operations costs (Karimi et al., 2015; Lu, 2009; Schmider et al., 2018),
better allocation of resources, and improve patient outcomes (Lewis & McCallum, 2019).
Implications for Social Change
The implications for positive social change include the potential to identify
strategies to assist in making pharmaceutical medicines safer for human consumption. PV

10
leaders can redirect the savings from PV operations toward investing in the actual PV
tasks like benefit-risk assessments of products, thereby improving patient outcomes and
making the products more efficacious and safer for human use. The savings from PV
operations could also be used to help or assist with community projects that could bring
about social change like building a new playground, putting in a community garden, or
creating a wheelchair fund that could be used to help purchase wheelchairs, walkers, or
assisted living devices to help persons achieve greater mobility and freedom in their
living environments. Companies can also use the savings to offer scholarships to students
pursuing courses and majoring in PV.
A Review of the Professional and Academic Literature
The purpose of this qualitative single case study was to explore the strategies that
PV systems managers in the pharmaceutical industry use to implement innovative
technology solutions to automate AE case processing. As observed by Saunders et al.
(2015), critical analysis and synthesis of the literature provided the context and
theoretical framework for my research relating to application of innovative technology
like AI or robotics-based solutions for PV. My goal was to identify knowledge gaps,
provide a foundation to legitimize the research question, and justify the current study and
research objectives (Azungah, 2018; Saunders et al., 2016). This section includes the
findings of an integrative review that I conducted to understand the function of PV and its
challenges, perspectives of technology on PV and AE reporting, and the conceptual
framework based on technology adoption models and theories.
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The literature review consisted of journal articles and book chapters (as shown in
Table 1) relating to the PV function focusing on technology and the pharmaceutical
industry, and the theoretical background of the technology adoption models specifically,
TTF and technology acceptance model (TAM), and chaos theory (Faggini & Parziale,
2016; Lorenz, 1963). The literature review included an integrative review of articles from
Walden University library, Google Scholar, PubMed, and ProQuest databases. Key
search terms for conducting research for the literature review included: technology
adoption, innovative technology, pharmacovigilance, drug safety, adverse reaction
reporting, adverse drug event reaction in combination with strategy, conceptual
framework, technology acceptance, TAM, TTF, chaos theory, and qualitative research or
a combination of keywords. Throughout the study, the terms AEs, adverse reactions, and
case reports are used interchangeably. The terms drug product, medicines, drug, and
product are used interchangeably. The study included 176 references out of which 141
(80%) were published in or after 2016.
Table 1
Source of Data for Literature Review
Total
Peer-reviewed journals

88

Total Published in
or After 2016
80

% Published in or
After 2016
91%

Books

2

2

100%

Non-peer-reviewed journals

15

14

93%

Total

105

96

91%

This academic literature review section is split into two subsections and is
structured as follows: (a) technology adoption models: TTF model, including TAM as the
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supporting model and chaos theory as the contrasting theory and (b) an introduction to
PV including health information technology: the importance of the PV function and AE
reporting for the health authorities, the pharmaceutical industry, automation, and
innovative technology implementation, including the challenges and risks. I present the
informatics and technology perspective including the challenges and opportunities.
Technology Adoption Models and Theories
Researchers have used the technology adoption models and diffusion theories to
build a foundation for studies to understand innovation adoption and diffusion (Jha &
Bose, 2016). In their study to understand the developments in the field of innovation
research in information systems, Jha and Bose (2016) analyzed articles published in the
past 15 years to conclude that technology acceptance models and diffusion theory are the
most popular. During the exploration for a conceptual framework for my study, I
analyzed technology acceptance models and decided on the task technology fit or the
TTF model. Diffusion theory is a change model for adoption of technological innovations
and helps in identifying the perception factors of innovation that influence adoption of
innovative technology (Emani et al., 2018). Because I focused on implementation of
innovative automation technology and not particularly perception of innovation and
adoption, I believed the TTF model constructs provided better guidance to achieve the
objective of this study. I have described The TTF model, and the applicability of the TTF
model constructs to this study in this section. Overreliance on a theory can lead to
confirmation bias with researchers looking for evidence to match the existing conceptions
(Collins & Stockton, 2018). Therefore, as guided by Collins and Stockton (2018), I used

13
the constructs of the TTF model as a tentative theory or a map to understand the
phenomenon.
TTF model. Goodhue (1995) proposed the TTF model to evaluate and measure
success of information systems and posited that a high task-technology fit would
positively impact the performance. Goodhue and Thompson (1995) proposed the TTF
model by empirically testing the link between IT and individual performance to assert the
utilization of technology and that the technology must be a good fit for the tasks it
supports. TTF links the task requirements, individual abilities, and the functionality of
technology (Goodhue & Thompson, 1995), as shown in Figure 1. Goodhue and
Thompson (1995) concluded their research based on data collected from questionnaire
responses from 600 individuals from two companies. Lai (2017) summarized the TTF
model as suitable for investigating the utilization of new technology solutions.
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Figure 1. Task-technology fit model constructs. Adapted from “Task-technology fit and
individual performance,” by D. L. Goodhue and R. L. Thompson, 1995. MIS Quarterly,
19(2), p. 213.
TTF is a simple model that matches the tasks with the ability of a technology to
address the events as they occur. TTF theory focuses on the application and the general
reliance on technologies and does not recommend any task or technology pairings that
could produce a strong effect (Howard & Rose, 2019). Common constructs are associated
with the outcome of the task and technology fit, like performance, user reactions, utility,
perceived utility, and utilization, and not the TTF model itself. Howard and Rose (2019)
believed that the narrow scope of TTF theory may be the reason for alterations and
inappropriate inferences, which may be rectified by extending TTF theory to better fit a
wide range of settings.
Taherdoost (2018) performed a literature review of technology adoption models
and noted that most information system researchers did not separate the affective
emotional component of attitudes of like/dislike and the cognitive component of
information a person holds about an object, issue, or person. Both cognitive processes
and emotional and affective elements influence behaviors (Taherdoost, 2018). Therefore,
integration of different models would help achieve the greater comprehensive view of the
objectives of the research (Sombat et al., 2018; Dishaw & Strong, 1999).
Researchers have improvised the TTF model by incorporating other theories such
as the technology-based models like TAM and the appropriation theories. TAM and TTF
are two foremost models of information technology utilization and adoption (Dishaw &

15
Strong, 1999; Lai, 2017). The integrated TAM/TTF model combines an
attribute/behavior model (TAM) with models of the task and technology fit with a
conclusion that TTF constructs directly affect technology utilization and indirectly affect
the technology utilization using TAM’s variables alone (Dishaw & Strong, 1999).
Dennis, Wixom, and Vandenberg (2001) introduced the fit-appropriation model by
integrating TTF with the appropriation support the group receives in the form of training,
facilitation, and software restrictiveness. Park (2019) proposed content characteristics
such as knowledge, information, and data as a new determinant of fit to improve the
explanatory power of TTF.
TAM. TAM was introduced by Fred Davis in 1989 (Davis, 1989) and is one of the
most widely used models for technology acceptance (Lai, 2017; Taherdoost, 2018). TAM
as a supportive model explains the causal relationship between a user’s acceptance of
technology and actual usage (Sombat, Chaiyasoonthorn, & Chaveesuk, 2018). TAM
identifies ease of use and perceived usefulness to determine the user’s attitude toward
technology, intention to use, and actual use (Dishaw & Strong, 1999). Researchers can
use TAM to explain the causal relationship between user’s acceptance of technology and
actual usage (Sombat, Chaiyasoonthorn, & Chaveesuk, 2018). TAM identifies ease of use
and perceived usefulness to determine the user’s attitude toward technology, intention to
use, and actual use (Dishaw & Strong, 1999).
Integrated TAM/TTF model. To understand the how customers use the software
and how the software functionality fits the perceived needs of the user, Dishaw and
Strong (1999) provided an integrated TAM/TTF model. Integration of TAM and TTF
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offers a stronger model because the variable constructs overlap in a certain way (Sombat
et al., 2018). Dishaw and Strong (1999) devised the integrated model based on study data
from questionnaire responses from three established firms from financial services,
aerospace manufacturing, and insurance industries. The questionnaire contained items for
each TAM variable: intention to use, attitude toward use, perceived ease of use, and
perceived usefulness (Dishaw & Strong, 1999). The integrated TAM/TTF model
combines an attribute/behavior model (TAM) with models of task-technology fit with a
conclusion that TTF constructs directly affect technology utilization and indirectly affect
the technology utilization using TAM’s variables alone (Dishaw & Strong, 1999). Since I
focused on selection and implementation of innovative technology in this study, the
constructs of the TTF framework was deemed to be a better match in achieving the
objectives of my study.
Chaos theory. Henri Poincare introduced the chaos theory with a principle that
systems tend to self-organize to adapt to continuing challenges to overcome chaos
(Faggini & Parziale, 2016). As a contrasting theory for this study, chaos theory can assist
in understanding of the unpredictability of a system’s behavior. To demonstrate the chaos
theory, Lorenz (1963) used the butterfly effect, which is a phenomenon that generates
small changes in the input but distributes dramatic consequences in the output. The chaos
theory helps researchers understand how complex systems work and what causes
ambiguity regarding the behavior of the dynamic systems.
In the perspective of technological innovation, Li and Wang (2019) found that
chaos of the system is visible when the technological content is larger. Therefore, Li and
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Wang (2019) summarized that companies use optimal technological contents to obtain
maximum profits. Since the innovative technology solutions are a recent development for
PV, the pharmaceutical companies implement and operate with optimal solutions to
balance the profit margins with the stability of the market (Li & Wang, 2019) despite the
need of using technological innovation to create competitive advantage.
Based on the literature review of original models and integrated models for
technology implementation, as described in this paper, I chose the TTF model for my
research study. Because a qualitative study is inductively grounded and based on
philosophical and ethical grounds, my research could have followed a structured or
unstructured approach, as guided by Cypress (2018). An inductive approach is used to
explore a phenomenon and identify themes to create a conceptual framework (Saunders,
Lewis, & Thornhill, 2015).
Researchers have applied the TTF model in a healthcare setting where business
needs technology solutions. Ali, Romero, Morrison, Hafeez, and Ancker (2018) applied
the TTF framework to evaluate how a patient portal helped improve the portal's fit to
patient needs. The study concluded that patients lack a clear understanding of tasks that
would help them accomplish personal health information management (Ali et al., 2018).
Because my research topic included new strategies PV systems managers use to
implement innovative technology, an unstructured inductive qualitative study based on
the constructs of the TTF model assisted in achieving my study objectives.
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PV and Healthcare Information Technology
In this section, I will describe the findings of the integrative review to understand
the business of PV and IT in the pharmaceutical industry. This section includes PVrelated topics such as the function of PV, mandated AE reporting, and related challenges
like product recalls and AE detection and reporting. This section of the literature review
also includes the perspectives of technology on PV and AE reporting, digital PV,
automation, innovative technology implementation trends and risks, and implementing
innovative technology for PV business processes.
PV. A search for approaches for pharmacovigilance or drug safety revealed a
variety of research studies. PV is studying the safety and effectiveness of drugs including
the activities relating to detection, assessment, understanding, and prevention of the AE
associated with the use of drugs (Beninger & Ibara, 2016; Lu, 2009; World Health
Organization, 2019b). A marketing authorization (MA) holder must prove a drug
product’s safety, efficacy, and quality to obtain a product license to market it (Lewis &
McCallum, 2019). A drug product or medicine will gain a marketing authorization after a
regulatory agency conducts comprehensive reviews of the drug product to evaluate the
benefits and risks (Schurer, Bam, & de Kock, 2017), finds a favorable benefit-risk
balance, and approves the drug product to be marketed within jurisdiction of the relevant
agency.
When a drug product is marketed, and the drugs are used by large populations,
unexpected adverse reactions or AEs may occur, which changes the risk-benefit ratio of
the drugs, requiring a regulatory action in post marketing surveillance (Pitts et al., 2016).
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AE is unexpected harm caused by the normal use of medication at the normal dosage
(Karimi et al., 2015). No medicine is safe at the time of approval for sale or marketing
authorization (Pitts et al., 2016). Only when the benefit of taking the drug outweighs the
risks, consuming a drug can be justified (Kothari et al., 2018). Since clinical trials are
conducted in a controlled environment with a small set of human patients, the adverse
reactions and AEs collected are not representative of the large population that will
consume the drug. AE from consuming drugs could remain undetected, exposing
consumers to the unexpected risks and harm in the absence of a robust AE reporting
system (Bailey et al., 2016). Therefore, the early detection, observation, and analysis of
AE in the post-marketing period to identify the risks associated with the consumption of
drugs (Munoz et al., 2020; Tan et al., 2016) and protect patients from unnecessary harm
is a key goal of a PV system.
Drug safety is a priority for both the health agencies worldwide and the
pharmaceutical industry. In the European Union, about 197,000 deaths are caused by AEs
per year and the total cost to society of AEs is €79 billion (Mohiuddin, 2018). AEs are
unexpected effects occurring from normal use of drugs taken in normal dosage (Basile et
al., 2019). In 2013, medical errors including AEs were identified as the third leading
cause of death in the United States (Makary & Daniel, 2016). Health authorities and
agencies have implemented multiple mechanisms to monitor the safety of the drug
products across the discovery, development, and marketed phases like the Center for
Drug Evaluation and Research (CDER), the New Drug Application (NDA), and Post-
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marketing Surveillance (PMS) program to assess and monitor drug safety risks by the
U.S. FDA (Tan et al., 2016).
Unsafe healthcare causes harm and leads to other forms of collateral damage such
as loss of trust in the system and loss of reputation and credibility in health services
(World Health Organization, 2017). The occurrence of AE is one of the top 10 causes of
death and disability across the world (World Health Organization, 2019a). Officials of the
World Health Organization reported that 134 million adverse events occur each year in
hospitals, contributing to 2.6 million deaths annually due to unsafe care (World Health
Organization, 2019c).
Drug product recalls. Delayed detection of AEs can lead to legal risks and huge
expense for a pharmaceutical company. Serious AEs can lead to drug recalls, market
withdrawals, and safety alerts and can cost the company financially and loss of consumer
trust and are an important safety issue for patients and healthcare providers (Hall et al.,
2016; Liu, Zhao, & Zhang, 2016). A review of U.S. FDA recalls showed that AE was one
of the top three reasons for drug recalls, which could cost a large pharmaceutical
company $900 million (Hall et al., 2016). 644 products were withdrawn from the market
because of AEs between 1953 and 2013 (Onakpoya, Henegan, & Aronson, 2016). The
withdrawal of anti-inflammatory rofecoxib (Vioxx™) occurred only after millions of
patients had been exposed, highlighting the need for earlier, more comprehensive data
reporting (Bailey et al., 2016). Evidence from spontaneous reporting of AE and clinical
research studies are used to support the decisions for revoking marketing authorization
and withdrawal of products (McNaughton et al., 2014). Therefore, pharmaceutical
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companies and MA holders must identify AEs at the earliest to avoid the expenses from
recalls due to AEs and assist with patient safety.
Sources of AE. MA holders are required to collect, and report AE cases reported
by patients by 2012 PV legislation (Kothari et al., 2018). Each national drug agency
collects its own AEs in a database, so do the MA holders. Companies use relational
databases to collect, store, and process AEs, which are linked to data warehouses that are
used for reporting AEs to the health authorities (Lewis & McCullum, 2019). Sources of
AE data include literature including mass media, clinical trials, observational studies,
spontaneous reporting data analysis, case reports, clinical, non-clinical, and preclinical
data (Onakpoya et al., 2016; Rasch et al., 2019; Schurer et al., 2017). Spontaneous
reporting systems contain high quality data and have been the primary source of AEs
traditionally (Kothari et al., 2018; Raschi et al., 2019). Recently due to increased
awareness, multiple countries allow patients to directly report AEs. Patient reporting is an
important source for AEs, which has increased recently despite challenges with reporting
systems and confusions with reporting (Inacio, Gomes, Airaksinen, & Cavaco, 2018;
Mohiuddin, 2018). Patients, manufacturers, and healthcare professionals report AEs
(Schurer et al, 2017) in variety of ways by phone calls, e-mails, and report directly to the
manufacturers and the health authorities or discuss on social media such as blogs and
social networking sites. Typical process of collecting, processing, and reporting AEs
within a MA holder company is shown in Figure 2.
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Figure 2. Typical process for AEs case processing and reporting within a marketing
authorization holder. Adapted from “Utilizing advanced technologies to augment
pharmacovigilance systems: Challenges and opportunities,” by D. J. Lewis and J. F.
McCallum, 2019. Therapeutic Innovation & Regulatory Science, p. 2.
High volume of cases reported creates a challenge for governance to perform PV
(Mitchell, Schuster, Smith, Pronovost, & Wu, 2016). Though there is an exponential
increase in the number of AEs reported, under-reported, inaccurate, and delayed post
marketing spontaneous cases is a challenge for PV (Elkin, Johnson, Callahan, & Classen,
2016; Pitts et al., 2016; Schurer et al., 2017). Traditional AE data sources such as
spontaneous reporting data, electronic health records, pharmaceutical databases, and
biomedical literature are limited by under-reporting ratio, privacy issues, high cost, or
long publication cycle (Yang & Yang, 2018). Despite being obligated to participate in the
PV process and spontaneous AEs reporting, pharmacists do not fully comply (Kopciuch
et al., 2019). Only 16% of pharmacists were found to be trained in PV in Poland
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(Kopciuch et al., 2019). Nurses generally report AEs since doctors are not engaged and
do not report AEs, which causes bias and missed critical diagnosis (Mitchell et al., 2016).
Under-reporting is a result of non-standard reporting process, inadequate knowledge of
reporting, negligence, time constraints, and gaps in safety information systems
(Mohiuddin, 2018). The median under-reporting rate was 94% (Lexchin, 2015). Only 510% of AEs are reported and about 95% of health care professionals do not report AEs
(Mohiuddin, 2018). Under-reporting of AEs could cause delays in making decisions
regarding withdrawing the drugs from the markets (Onakpoya et al., 2016). Standardizing
reporting and encouraging patient reporting by creating a safe and secure environment
can improve voluntary spontaneous reporting and reduce incomplete and insufficient data
(Schurer et al., 2017). Padgett, Gossett, Mayer, Chien, and Turner (2017) recommended
organizations transition into high-reliability organizations in order to increase AE
reporting, which could contribute to industry-wide improvement in patient safety and
reduce operational costs.
The information about the type and variety of AE data elements collected within
AE reporting systems varies internationally. Timely communication of AEs is a challenge
though the AEs are recognized sooner (Lexchin, 2015). Bailey et al. (2016) identified 108
reporting systems, containing 1,782 unique data fields mapped to 33 reporting concepts.
A minimum required dataset for a valid AE case report included an identifiable patient,
an AE, a suspect medicinal product, and an identifiable reporter. However, the absence of
standardized AE data collection and reporting data elements and variations across
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systems rendered aggregate reporting a challenge, which directly affected safety
surveillance (Bailey et al., 2016; Schurer et al., 2017).
With the increase in awareness about AE reporting, regulatory agencies have
improved their safety surveillance guidance for the MA holders (Stergiopoulos, Fehrle,
Caubel, Tan, & Jebson, 2019). Since the spontaneous reporting of AEs is biased with
challenges, PV function leaders from the industry and the regulatory agencies are
exploring other sources and advanced computational methods to supplement existing
methods (Basile et al., 2019; Toki & Ono, 2018). Many researchers have concluded that
social media is a good source of AE information and that technology can be used in
social media mining to find cases (Pitts et al., 2016). However, based on a systematic
review, Convertino, Ferraro, Blandizzi, and Tuccori (2018) concluded that despite the
possibility of mining AE data quicker from social media than traditional spontaneous
reporting, the poor quality of information makes it a challenge for social media to be
considered a viable source of AE for PV. The user posts on social media contain
colloquial language and misspellings, which disrupts the balance between sensitivity and
specificity in identifying AEs (Raschi et al., 2019).
The current process of collecting and processing AE in the pharmaceutical
industry is manual, complex, and poses high risk of errors. The challenges on the
pharmaceutical industry’s perspective include the management of the high volume of
AEs, globally diverse and changing regulations, complex and evolving systems, and
sparse PV expertise and talent (Price, 2018). In 2019, the U.S. Food & Drug
Administration received 2.2 million AEs (“FDA adverse event”, 2019), which is a 450%
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increase since 2009 and increased AE-related operational costs for pharmaceutical
companies. Pharmaceutical companies must invest in PV to avoid risks and frequently
manage PV as a cost-center. Processing of an AE is an expensive resource-intensive
process, which includes high risk of errors and operational inefficiencies (Ghosh et al.,
2020). The increasing costs of PV have led to outsourcing of PV activities to service
providers operating in low-cost locations (Price, 2018). A continuous, digitized,
automated data management within a computerized system that leverages AI, machine
learning, and blockchain can address the talent shortfall (Price, 2018) and refocus the PV
effort from data management toward ensuring effective use medicines.
Healthcare information technology. Healthcare information technology is the
application of computers for the storage, retrieval, sharing, and use of health care
information, data, and knowledge for communication and decision making (Alotaibi &
Federico, 2017). Marante (2018) posited that clinical experience could not be
contemplated in the algorithms, and that contributes enormously to the establishment of
the causal relationship between a product and AE. However, Marante (2018) concluded
that the clinical judgment method poses difficulties in standardization of evaluation; and
therefore, a need for a universally accepted high-quality assessment tool.
Recently, innovative technologies are impacting the way companies process and
evaluate AEs. Beninger and Ibara (2016) and Donzanti (2018) summarized that the
rapidly developing innovations in informatics pose challenges for PV, however, offer
opportunities for close collaboration. Innovative technologies like robotics and AI have
permeated the pharmaceutical industry and assist in enhancing the drug discovery process
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and reducing the research and development effort (Agrawal, 2018; Donzanti, 2018).
Implementing AI technologies can be a breakthrough for the future market sustainability
of biopharmaceutical organizations (Agrawal, 2018).
Automation. The pharmaceutical industry is actively engaged in an automation
race. Automation is an intelligent organizational process that delivers responsiveness and
agility, which is created as an outcome of effective usage of technology like robotics
(Buyukozkan & Gocer, 2018). Automation accelerates innovation by increasing
productivity and relieving human resources, which can lead firms to gain significant cost
and competitive advantages (Bal & Erkan, 2019; Nylund, Ferras-Hernandez, & Brem,
2018). Technology and innovation are two of the five top factors leading to economic
success (Bal & Erkan, 2019). Expert systems use an inference or cognitive engine, which
provide information by replicating the decision-making processes performed by a human
expert (Tomita, 2019). Investing in and implementing emerging technologies will create
a sustained competitive advantage for companies through enhancing access to
information, reducing costs, improving products quality, as well as responsiveness, and
collaboration abilities (Agrawal & Narain, 2018). By investing in automation, companies
generate value by lowering expenses on human resource and increasing revenue and
productivity though process innovation (Nylund et al., 2018). Companies who have
embraced digital strategies are seeing real value, boosting revenue more than 9%, market
valuation more than 12%, and profitability by over 26% (Rakowski, 2015).
Pharmaceutical industry as a business sector is a slow adopter of new and
emerging technology for automation like artificial intelligence (Lewis & McCallum,
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2019; Streefland, 2018). Most healthcare organizations face challenges to innovate in
terms of management, systems, and culture, despite recent innovation practices like open
innovation and innovative management practices (Kim, Gaukler, & Lee, 2016).
Companies attempt to incorporate automation into all functions, including research and
development (R&D) and PV. For example, cognitive technology-based systems like IBM
Watson can leverage Big Data to improve insight and accelerate life sciences discoveries
(Chen, Elenee Argentinis, & Weber, 2016). Investing in automation in PV can provide
better quality of safety data quickly with lesser manual effort (Lewis & McCallum,
2019). PV systems managers focus on the development, acquisition, and incorporation of
related technologies to profit from automation. Most companies partner with suppliers
who possess the expertise with automation technologies and invest in co-innovation
based on a knowledge sharing and open innovation strategy (Nylund et al., 2018;
Trantopoulos, von Krogh, Wallin, & Woerter, 2017). Another critical aspect is
organization culture.
An organization must have a common culture that is aligned with the
organizational goals. Organizations are exposed to technology, globalization, and cuttingedge production, which result in creation of new organization structures, business
processes, and ways of working (Fusch, Fusch, Booker, & Fusch, 2016). Leaders must
invest in building a resilient organization with an innovative culture that can withstand
the exposure and maintain their competitive edge.
While planning for a digital future, company managers must critically evaluate
the technologies and business models they can adopt to reach their objectives. Selecting
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the most suitable technological solutions and reaping the maximum benefits of the digital
means requires companies to internalize digitalization as an integral part of their overall
operations methodology and their organizational structure (Buyukozkan & Gocer, 2018).
Dalenogare, Benitez, Ayala, and Frank (2018) recommended companies targeting
differentiation focus on product development technologies and those targeting low cost,
productivity or operational flexibility can prioritize manufacturing technologies.
Innovative technology implementation trends. Organizations can incorporate
innovation externally from a supplier or partner by joint development, which is more
suitable for customer-supplier collaborations. With an emphasis on external collaboration
to encourage and implement open innovation, Rodriguez-Ferradas and Alfaro-Tanco
(2016) presented strategies for small and medium enterprises to collaborate with different
kind of partners. For example, innovation contests can be used for company-university
collaborations.
Organization leaders have realized that proactive external collaboration is
beneficial for creation of new products and solutions (Di Fiore, Vetter, & Capur, 2017).
Di Fiore et al. (2017) identified four specific areas of benefits:
•

deeper knowledge: collaboration between experts and end users offers indepth knowledge of the business context of use.

•

lower marketing costs: collaboration based on joint development and
testing partnership can lower marketing costs.

•

decreased risks: innovation driven by direct collaboration with the end
users produce solutions with lower risk and fit the business purpose better.
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•

increased trust: close collaboration improves relationship and increase
trust between the partners.

Different open innovation practices can be utilized for new product development
in companies collaborating with different kinds of partners (Rodriguez-Ferradas &
Alfaro-Tanco, 2016). Organizations must internalize digitalization and incorporate in the
operations methodology and structure in order to select the most suitable technological
solutions and reap the maximum benefits (Buyukozkan & Gocer, 2018). Rose, Jones, and
Furneaux (2016) and Trantopoulos et al. (2017) identified knowledge, innovation
management, and the team process as the significant innovation drivers in small and
medium sized enterprises.
Organizations engage in outsourcing of transactional systems to enable service
innovations or new product development in the form of contract agreements (Susarla &
Mukhopadhyay, 2019). Automation and cognitive systems have permeated service
management to a next generation of integrated network, systems, and service
management (Keller, 2017). Service management is built based on service level
agreements with the outsourcing partner, which can be hosted on cloud or traditional or
hybrid setups blending cloud with traditional or virtualized on-premise infrastructure
(Keller, 2017).
To enable business model innovation, organizations with inhouse digitization and
IT development capabilities can adopt agile development methodology. Agile
development refers to practices for software development based on iterative and
incremental delivery of working software, collaboration with customers and response to
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change (Ghezzi & Cavallo, 2018). Managers have multiple options to implement
technologies and value propositions and adopt a leader or follower strategy in the
digitization arena (Ritter & Pedersen, 2019). Since innovative technology does not
provide any guarantees, companies leverage iterative ideation and experimentation.
Innovative technology risks. There are multiple risks associated with using
technology for competitive advantage. Thorough analysis of all innovation stages is
required when innovation is considered, owing to the complex multistage nature of the
innovation process and lifecycle (Jha & Bose, 2016). Carr (2003) called IT a commodity
and strongly recommended focusing on the risks rather than the strategic advantages it
provides. A disruption to IT supply can paralyze a company. Overspending on IT can
place a company at a cost disadvantage. Sourcing of technology development, support,
and management of IT functions from vendors introduces risks. Companies must
carefully invest in technology and IT solutions because great spending on IT does not
equate to superior financial results (Carr, 2003).
Managers might not understand the implications of disruptive technologies
because their views of the world are shaped by their prior experiences of technologies
and markets (Vecchiato, 2017). Innovative technology can lead to cultural changes in the
organizations progressing toward building a smart, creative and dynamic innovation
culture (Keles, & Battal, 2017). Change is difficult, the managers must use the right
strategies to communicate and motivate the team members to build an innovative culture
(Eggers & Kaul, 2016).
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Despite the various advantages and benefits of external collaboration for
innovation initiatives, many innovations fail to deliver the expected successful outcomes
and lead to significant value creation (Di Fiore et al., 2017). Di Fiore et al. (2017)
identified the following four traps that collaboration can lead to and potential solutions to
avoid them:
•

treating collaboration as an event. Instead, manage collaboration like a
seamless process. Innovation requires careful planning, agreeing on waysof-working, intellectual property management, resource management, and
defined oversight and governance.

•

defining the problem statement alone. Instead, co-design the problem
statement. All the parties and stakeholders involved must be in complete
agreement on the problem that is being solved to ensure the solution
matched the business need and problem.

•

diverging time horizons. Instead, generate value across multiple time
horizons. Shared understanding of the timeline expectations will drive the
resource allocation and management, which will directly impact the
financials. Time span and financial goals must be defined upfront with
transparency.

•

failure to generate empathy. Instead, empathize throughout the process.
During the collaborative innovation process, the stakeholders must include
the human or end-user perspective in the ideation stage of the process.
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Digital PV. Digitalization involves using digitized data to make decisions and
generate change (Gobble, 2018). Gobble (2018) further explained that the digitalization
process leads to digital transformation, which is the re-structuring and re-defining of the
business organizations considering opportunities from emerging technology. Digitization
and innovations like Big Data and analytics have led to new operating models in multiple
functions within healthcare industry, but, not PV (Beninger & Ibara, 2016). Karimi et al.
(2015) summarized that drug safety had not been comprehensively surveyed from the
viewpoint of computer science to understand the influence of technology on drug safety
detection.
Schmider et al. (2018) summarized that despite the significant opportunity
provided by PV, there are no comprehensive technology solutions for expensive processAE processing and reporting. Beninger and Ibara (2016) concluded that both the fields
PV and informatics have separately grown exponentially, with a substantially low rate of
overlap between the two despite the increase in awareness of innovative technology in
PV. Beninger and Ibara (2016) presented a detailed analysis of the PV adverse event case
processing process and the corresponding technology used starting from relational
databases and faxes to the recent technology like Blockchain and artificial neural
networks. Beninger and Ibara (2016) identified advanced technology like AI for PV is
emerging and growing and concluded with an emphasis for implementing informatics
and developing structures to facilitate an approach to adopt informatics. Prior to
deploying automation, organizations must embark on a business process re-engineering
journey (Mishra, Devi, & Narayanan, 2019).
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In 2014, the FDA received 528,192 new AE reports indicating a serious or fatal
outcome, 4.7% directly from health professionals and consumers, and 95.3% from drug
manufacturers (Moore, Furberg, Mattison, & Cohen, 2016). Majority of the AEs received
by the FDA are from the manufacturers and MA holders since most AEs are reported
directly to the manufacturers (Stergiopoulos, Brown, Felix, Grampp, & Getz, 2016). A
study on AE quality and completeness by Moore et al. (2016) concluded that the report
completeness from drug manufacturers was poor compared with direct submissions.
More than one third of the AEs submitted by the manufacturers did not include basic
information to establish a causal relationship between an AE and a drug product, which
can be an issue for the detection of safety signals (Plessis, Gomez, García, Cereza, &
Figueras, 2017). Innovative technology including new algorithms and data mining tools
can assist in improving the quality and timely extraction and reporting of AEs (Lewis &
McCallum, 2019; Plessis et al., 2017). The future of adverse event reporting had to take
full advantage of the rapidly developing electronic health records and technologies to
automate voluntary reporting of incidents (Mitchell et al., 2016).
A study by Ribeiro, Motta, Marcondes-Fonseca, Kalil-Filho, and Giavina-Bianchi
(2018) revealed that in a hospital setting, there were a total of 94 adverse drug reactions
in 75 patients and most reactions were predictable and of moderate severity. For each
medication introduced during hospitalization, there was a 10% increase in the rate of AEs
with the probability of observing an AE was 1 in 104 patients per day. 134 million AEs
occur each year in hospitals, contributing to 2.6 million deaths annually due to unsafe
care (World Health Organization, 2019c).
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Proactive prevention of risks can be achieved using AI for analysis of data from
post marketing studies, electronic medical records, and the Internet among other trends
(Fermont, 2019). Organizations must understand and identify the opportunities and
implications of implementing innovative technology to add value at a conceptual level
(Lewis & McCallum, 2019) as shown in Figure 3. Despite multiple successful
experiments with using innovative technologies to improve performance and efficiency,
the primary challenges are transparency and traceability (Spasic, Uzuner, & Zhou, 2020).

Figure 3. PV systems automation: Conceptual diagram showing the different entities
relating to PV systems automation. Adapted from “Utilizing advanced technologies to
augment pharmacovigilance systems: Challenges and opportunities,” by D. J. Lewis and
J. F. McCallum, 2019. Therapeutic Innovation & Regulatory Science, p. 2.
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Leaders must adopt a systems thinking approach and focus on systems, processes,
and measures to build a learning organization which is both reliable and resilient
(Gossett, Padgett, Pierce, & Scott, 2019). Emerging technology and intelligent
automation in the PV business systems function is complex, and are not readily
understandable by the PV business professionals who are trying to implement them
(Lewis & McCallum, 2019). Eseryel (2019) summarized three strategies for non-IT
managers to achieve digital business transformation: create and procure endorsement for
an IT-enabled business transformation vision, develop a change management function for
the transformation, and build a strong non-IT business leadership team.
Lewis and McCallum (2019) envisioned all stakeholders within the PV industry
working on a single database that is based on blockchain technology. Arlett, Straus, and
Rasi (2019) made three predictions for PV, by 2030 PV function will be smarter in
collecting and reporting of AE, measurement of on‐market performance of medicines,
and improved engagement of patients and healthcare professionals. Streefland (2018)
highly recommended the PV system to focus on the patient rather than on regulations and
recognized a need to work toward optimal analysis of real-time medicine use insights,
instead of AE creation, reporting, and adherence to procedures.
Innovative technology trends in PV. Mesko (2017) recognized that medicine
requires a variety of disruptive technologies to be implemented into developing
treatments, practicing medicine, and delivering care. Recent developments in the
innovative technologies include text analytics, robotic process automations, cognitive
technologies including machine learning and deep learning. Since rule-based
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technologies are traceable, the applications are abundant. Despite multiple successful
experiments with using these innovative technologies to improve performance and
efficiency, the primary challenges are transparency and traceability (Spasic et al., 2020).
Ghosh et al (2020) considered the innovative automation technologies like natural
language processing (NLP), AI, machine learning, optical character recognition, and
robotic process automation (RPA) as “intelligent” since they are more advanced. Ghosh
et al. (2020) also predicted that the risk of failure or malfunction of these technologies
will reduce over time as the technologies evolve. The automation requirements for small
and mid-size companies might be different from large companies since they may have
specific process approaches that may not be conducive for automation (Ghosh et al.,
2020).
RPA is an automation technology that can be used enterprise-wide to automate
repetitive manual processes which are rule-based, thereby enabling manual resource cost
savings, reducing errors, and improving efficiency (Dey & Das, 2019). Carden,
Maldonado, Brace, and Myers (2019) listed accuracy, audit trail, consistency, flexibility,
location agnostic, low-risk and non-invasive technology, productivity, reliability,
availability, and productivity as the value proposition for RPA. RPA software robots
(bots) only work on the user interface, which are simple to develop and do not require
complex programming (Phillips & Collins, 2019). Phillips and Collins (2019) compared
bots, which follow a set of rules with AI-based solutions, which are neural networks
designed to replicate human brain process. Since bots are straight forward and rule-based,
they can be built to replace any repetitive and mundane tasks and applied in any industry.
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RPA can be applied successfully for PV; however, the PV systems managers and the
business users must work closely to identify highest potential processes and identify the
most beneficial automation approach (Carden et al., 2019; Phillips & Collins, 2019).
Innovative technology must be used intelligently. For example, processes that involve
decision making, the RPA solutions must be blended with AI-based cognitive solutions
(Mishra et al., 2019)
Multiple researchers have identified a variety of applications for text analytics in
the healthcare and pharmaceutical clinical functions such as triaging patients, decision
support, clinical research, and PV (Spasic et al., 2020). In the recent years, clinical NLP
systems have matured to accurately extract medical information buried in texts that
contribute to PV (Tan et al., 2016). Schmider et al. (2018) conducted a pilot test to verify
the feasibility of using AI and robotics to automate the processing of AE reports. The
results confirmed the viable use of AI-based solutions for AE case processing regarding
extraction of case information by training the machine learning algorithms (Schmider et
al., 2018). NLP can structure and customize automatically extracted AE information and
store in a way that healthcare professionals can specifically share AEs that are of the
individual patients’ interest (Kusch, Zien, Hachenberg, Haefeli, & Seidling, 2020). NLP
can be used to detect healthcare associated infections in hospital facilities and NLP chain
processing can facilitate a standardized AE detection process across multiple hospitals
(Tvardik et al., 2018).
Social media is a potential rich source of AEs. Considering the median underreporting rate of AE to be 94% in spontaneous reporting systems, social media and

38
crowd-sourced data can be potential sources to detect AE related to health products
including pharmaceuticals, medical devices, biologics and natural health products
(Tricco, Zarin, Lillie, Pham, & Straus, 2017). Despite the possibility of mining AE data
quicker from social media, poor quality of information makes it a challenge for social
media to be considered a viable source of AE (Convertino et al., 2018). Data from social
media is not rich because of the use of slangs and colloquial posts, which cause a
negative impact on the AE extraction program (Arnoux-Guenegou et al., 2019). In their
study, Gattepaille, Hedfors Vidlin, Bergvall, Pierce, and Ellenius (2020) concluded that
there was a large discrepancy between the expected and actual results of automatically
identifying AEs from Twitter. The authors justified the lack of an all-purpose automated
social media AE extraction solution in the industry was potentially due to the challenges
with practical AE detection from independent data.
Complex medical concepts can be extracted from informal, user generated
content. Nikfarjam, Sarker, O’Connor, Ginn, and Gonzalez (2015) devised a machine
learning-based approach that was scalable and suitable for social media mining, as it
relied on large volumes of unlabeled data, which removed the need for large, annotated
training data sets. Yang and Yang (2018) developed a framework to facilitate drug safety
signal detection by harnessing online health community data, a timely, informative, and
publicly available data source like MedHelp, which collected patient-contributed content.
Advanced NLP techniques like feature-based and kernel-based methods that can
effectively identify and separate AEs and non-AEs from the informal text in the social
media (Liu et al., 2016).
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Cognitive technologies have proven to successfully detect AEs in experimental
setting. Based on multiple pilot projects, Chen et al. (2016) summarized that IBM Watson
can assist the drug safety process through faster recognition and coding of AE from text.
Watson can be used to improve the efficiency of existing drug safety personnel and
support timely reporting of AEs to regulatory agencies.
Machine learning models pose risks when PV managers must justify the decisions
made by the system in the event of a health agency inspection or an audit. PV managers
must ensure they understand the implicit rules that the machine learning models use to
make the decisions (Tomita, 2019). A combination of a machine learning approach and
human review can be a potential effective and scalable solution for AE detection from
social media (Comfort et al., 2018). Automated identification using machine learning
models is a more efficient way to provide initial review of AEs and the human resources
can be redirected to review and remedial actions more quickly to respond to emerging
safety issues (Wang, Coiera, Runciman, & Magrabi, 2017).
Negi, Pavuri, Patel, and Jain (2019) proposed a novel method of combining
machine learning and NLP technology to assist with automating AE and suspect drugs
extraction from medical reports. The first method tried to establish a causal relationship
between the drug and the medical condition. The second method classified a drug into a
suspect drug or a non-suspect drug using NLP features and machine learning for
classification. Deep learning-based models and multi-task learning-based models can
assist NLP in significantly improving the probability of identifying and extracting AEs
from electronic health records (Li, Liu, & Yu, 2018). Most methods use annotated
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datasets to predict AEs, neural nets, attention mechanisms, and multitask learning are
popular choice for NLP applications for PV (Basile et al., 2019). Basile et al. (2019)
noted that the use of machine learning and deep learning are common in academic
research for PV but are not used in practice in the industry yet.
Blockchain technology stores data in a list of securely linked blocks. Blockchain
technology is currently widely used in the financial industry (Lewis & McCallum, 2019).
Blockchain can be adopted for PV where the PV system is contained within a single
protected environment. Lewis and McCallum (2019) envisioned a blockchain-based
centralized PV system used by the various stakeholders in the future.
Physicians can use innovative technology systems to predict an occurrence of AE
before prescribing new medicines. Lee and Chen’s (2019) developed a machine learningbased conceptual framework to predict the occurrence of AE which can benefit drug
manufacturers, healthcare providers, and patients. Dynamic systems can be integrated
into PV, thereby enabling predictive analytics and reasoning. However, due to the lack of
regulatory guidance and problems with system validation, implementing and adopting
dynamic intelligent systems is a challenge (Lewis & McCallum, 2019).
Strategies for implementing innovative technology in PV. Regulatory agencies
worldwide have improved and changed their safety monitoring processes, which has led
to increased reporting requirements (Stergiopoulos et al., 2019). Due to the changing
regulations for safety surveillance, MA holders in the pharmaceutical industry create new
internal processes or include new data sources to detect AEs (Stergiopoulos et al., 2019).
Multiple factors determine the successful implementation of innovative technology
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including the approach and strategy, types of data, and change management. Alotaibi and
Federico (2017) presented that the same technology used in different companies produce
varied outcomes. Different kinds of data can be handled with different technology
solutions like machine learning for unstructured data (Karimi et al., 2015).
In their study focused on PV operational costs and drivers, Stergiopoulos et al.
(2019) reported that several companies out of the 12 that participated in the survey had
plans for including automation technology like machine learning. But none had
implemented them as of 2018. Outsourcing was considered as one of the strategies for
organizations to focus on the core competencies, reduce costs (Mishra et al., 2019), and
eliminate internal resources. However, most companies are bringing PV operations back
in-house due to operational inefficiencies and increased risks (Stergiopoulos et al., 2019).
The impact of innovative technology solutions on the organizational structure and
job profiles will be evident since the AI solution will replace certain manual processes.
Beninger (2018) emphasized on the new skillsets, which will define the roles of the next
generation of professionals who perform PV activities. Mesko et al. (2018) identified
human resource crisis like accessibility and shortages in healthcare. Although Mesko et
al. (2018) did not directly associate the resource problems to PV in the article, the authors
concluded that the gaps in the human resource could be filled using advanced
technologies like AI. Mesko (2017) strongly recommended that data analysis solutions
must be implemented to support the skills of physicians and must not replace the
traditional physician–patient relationship. Organizations must expect to supplement the
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human workforce with expert systems and AI that can provide aggregated information for
making decisions (Tomita, 2019). However, AI also raises ethical questions.
Digital transformation includes alignment of technology with the company’s
culture, people, structure, and tasks (Kiron, Kane, Palmer, Phillips, & Buckley, 2016).
The human and technology relationship should also include user training, interaction, and
collaboration sub-goals in order to be effective (Oyekan et al.,2017). While concluding
that automation technology like deep learning can support with managing the AE
volume, complexity, and time constraints of AE report processing, Routray et al. (2020)
emphasized that human intervention will be required, and the technology must only
augment human review of AE seriousness. Internal drivers of a company, specifically,
organizational culture and environmental issues must be considered to leverage
advantages of data analytics (Hawley, 2016). A smart, creative, and dynamic innovation
culture will help organizations to see the value of invention (Keles & Battal, 2017). Ali
and Khan (2019) identified two categories of assessing organizational readiness for
implementing business intelligence: readiness of managerial proficiency and readiness of
information systems environment. Mishra eta l. (2019) strongly recommended that
organizations must setup a governance structure like center of excellence for the
automation and digitization initiatives.
AEs have increased exponentially over the years, and the processing and reporting
impose substantial costs (Karimi et al., 2015; Schmider et al., 2018). Cost of
implementing innovative technologies is high, which can be offset by savings postimplementation (Mesko, Hetenyi, & Gyorffy, 2018). Automated identification can help to
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find misidentified incidents and enhance data quality (Lewis & McCallum, 2019; Wang
et al., 2017). Stergiopoulos et al. (2019) noted that all PV leaders believed implementing
AI-based solutions will decrease costs for PV operations including simplifying AE
detection and processing. Data mining, machine learning, AI, and robotics can be used to
reduce costs and improve efficiency (Karimi et al., 2015; Lu, 2009; Schmider et al.,
2018). Therefore, pharmaceutical companies use technology increasingly to automate
various tasks within PV.
To enable adoption, PV managers must create a vision and project new
technology as a product designed to create, attract, and satisfy demand (Gherasim, 2011).
Creating mission statements is the first step in strategic management establishing
objectives, formulating strategies, and communicating with the customers (David, David,
& David, 2014). All stakeholders must provide endorsement and work toward making a
digital future a reality. PV managers must ensure the technology solutions are aligned
with the business needs and led by business operations (Mishra et al., 2019). Aligning
business needs with IT governance and executive management IT competence had a
strong and positive effect on innovation (Heroux & Fortin, 2018). Managers must
implement technology solutions that improve employees’ job satisfaction by matching
the task requirements and long-term professional needs (Wang, Wang, Zhang, & Ma,
2020).
Mishra et al. (2019) summarized that business process simplification,
standardization, and re-engineering are the critical factors for a successful automation
strategy. IT solutions alter business processes and existing work patterns leading to re-
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training and re-learning, which could increase employees’ work-related stress (Wang et
al., 2020). Training and re-learning initiatives assist in preparing and guiding the in-house
staff for digital transformation (Mishra et al., 2019) and to incorporate and blend RPA
and AI bots in their daily job. This will assist in adoption of innovative technology by the
employees.
Social influence can be a moderating factor for both adoption and resistance of
innovation. Social influence can reduce innovation resistance for inexperienced users
potentially through usage (Matsuo, Minami, & Matsuyama, 2018). To enable adoption of
innovative technology, which could change the role or even replace a human user, leaders
much perform effective change management, which transforms the way people perceive
innovative technology solutions.
Transition
The purpose of this qualitative single study was to explore the strategies used by
PV systems managers to implement innovative technology solutions to automate AE case
processing. I used the conceptual framework to understand the strategies provided by the
participants to address the research problem identified in Section 1. In Section 1, I
covered the key elements of the study including the problem statement, its purpose,
research question, conceptual framework, and a review of literature. In Section 2, I
provide justification for the selected research method and approach that was used for this
study, including my role as the research instrument, the population, participants and
sampling, data collection, analysis, and reliability and validity of the study. Upon
approval from the IRB, I contacted my participants, collected the data, performed data
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analysis, and then expanded this study to include the data analysis and findings. In
Section 3, I describe the findings of the study, recommendations for future research,
reflections, and conclusion.
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Section 2: The Project
In this section, I discuss the design of this single case qualitative study by
restating the purpose of this study and including the role of the researcher, participants,
research method and design, population and sampling, ethical research, data collection,
data analysis technique, and reliability and validity.
Purpose Statement
The purpose of this qualitative single case study was to explore the strategies that
PV systems managers in the pharmaceutical industry use to implement innovative
technology solutions to automate AE case processing. The target population consisted of
four PV systems managers working in a pharmaceutical company located in the Boston
area of Massachusetts, United States, who had used successful strategies to implement
innovative technology solutions to automate AE case processing. The implications for
positive social change include the potential to improve patient safety by identifying
successful strategies that PV systems managers can use or adapt to implement innovative
technology solutions to automate AE case processing.
Role of the Researcher
The researcher plays a critical role in conducting a research. The inquirer is the
primary data collection instrument performing the data collection and analysis activities
in qualitative research (Cypress, 2018). As the researcher, I conducted this qualitative
single case study using interviews as the primary method to gather information. I served
as the data collection instrument by enrolling participants and interviewing them using
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open-ended questions and collecting and analyzing the data from the semistructured
interviews.
My employment in the pharmaceutical industry and the professional relationships
I have established may have influenced the participants’ willingness and interest to
participate in this study. I have interacted with other PV industry leaders and managers as
a part of my professional engagement at my place of work. Though social relationships
and personal contacts of the researcher can be leveraged, the researchers must build a
respectful and trusting relationship with the participants and the relationship could lead to
bias (Joseph, Keller, & Ainsworth, 2016). As the researcher, I ensured that data collection
and analysis were objective by assessing the implications, as stated by Cypress (2018)
and decreasing my personal views about the phenomenon in an attempt to minimize and
mitigate bias and help achieve research integrity as recommended by Overgaard (2015).
Because I was familiar with my research topic, I used bracketing during the research
process by listing all my assumptions prior to data collection and including them as a part
of the study data analysis to identify any potential bias. I used one of the many methods
of bracketing to minimize bias. Reflective journaling as a method of bracketing can be
used to identify researcher’s preconceptions toward the research topic before or during
the research process (Tufford & Newman, 2010). I used reflective journaling as a method
to identify my assumptions regarding the research since I worked in the PV systems
function in a pharmaceutical company. Triangulation strategy is used to reduce risks and
remove systemic bias (Cypress, 2018). I used multiple data collection methods like
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semistructured interviews, documents and presentations, and the reflective journal to
facilitate triangulation.
I used semistructured interviews to understand the strategies that the PV managers
use to implement innovative technologies. Interviews provide a more complete picture of
the phenomenon by reconstructing and interpreting the past (Cypress, 2018). Good and
actionable questions are used to gather rich and deeper understanding of the issues and
events (Jonsen, Fendt, & Point, 2017). In order to regulate the interview procedure and
maintain control (Leonidaki, 2015) and enable consistency and inform participant about
their rights (Castillo-Montoya, 2016), I established an interview protocol (Appendix A)
to conduct the interviews. I captured notes and audio recorded the interview upon
receiving consent from the participants. I requested additional documents from the
participants and reviewed any publicly available information. I transcribed the
information gathered and subjected it to triangulation and member checking.
I used the Belmont Report to guide my ethical behavior during this study. The
Belmont Report focused on three ethical principles and their applications to conduct
research. Informed consent, risk/benefit assessment, and selection of subjects of research
requirements cover the principles-respect for persons, beneficence, and justice (National
Commission for the Protection of Human Subjects and Biomedical and Behavioral
Research, 1979). I adhered to the three principles by using confidentiality procedures to
protect the participants and maintain privacy. By explaining the study objective, the
interview process, the use of data collected, and obtaining informed consent, I mitigated
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ethical issues as recommended by Cypress (2018). I will store the data collected in a
password-protected flash drive and duly discard after 5 years.
Participants
I purposively selected a pharmaceutical company in the Boston area of
Massachusetts, United States as the single case for this study. Qualitative studies that aim
to explain a phenomenon in a specific context tend to use a purposive sampling design
(Sovacool, Axsen, & Sorrell, 2018; Tobi & Kampen, 2017). The primary criteria for
selecting the participants for this single case study included systems managers in the PV
or Safety department related to the PV Systems function employed in the selected
company. The participants were involved in successfully developing and implementing
innovative technology strategies to automate AE case processing and were willing to
participate in this study.
Researchers must gain access to the qualified individuals who must be willing to
participate in the study (Peticca-Harris, deGama, & Elias, 2016). I obtained authorization
from Walden University’s Institutional Review Board (IRB). Walden University’s
approval number for this study is 04-24-20-0972741 and it expires on April 23, 2021.
The number of participants depend on the characteristics of population from which they
are chosen (Saunders & Townsend, 2016). I identified eligible and qualified employees
for this study prior to inviting them to participate.
The relationship between the researcher and the participant is crucial. The
participants must be at ease to respond honestly to the questions, therefore, building trust
and establishing a respectable relationship are imperative (Malterud, Siersma, &
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Guassora, 2016; Yin, 2018). To build the relationship, I followed the best practices
suggested by Yin (2018) for credible qualitative research. I explained the objective and
the process of the study to the participants and obtained their willingness to participate. I
established a professional working relationship with the participants by talking to them
over the phone and maintaining confidentiality.
Research Method and Design
The research method and design define the intention of the study and represent
the characteristics of the proposed research. In addition, the method and design connect
the study with the procedures for data collection and data analysis processes (Ward,
Comer, & Stone, 2018). Research methodology impacts theory development, the
analysis, research duration, and the outcomes of the research (Saunders et al., 2015). In
this section, I justify the reasons for deciding to conduct a qualitative case study to
explore the strategies used by PV systems managers to implement innovative technology
solutions for AE case processing automation.
Research Method
A research method guides the investigators to obtain answers to the research
question while ensuring rigor in the research and reliability of results (Dresch, Pacheco
Lacerda, & Cauchick Miguel, 2015). There are three types of research: qualitative,
quantitative, and mix-methods research (Yin, 2018). During the research for a
methodology, I considered all the three types of research. Upon detailed research, I
decided to conduct a qualitative study to explore the strategies managers use to
implement innovation technologies.
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The primary purpose of my study was exploration, with a pursuit of identifying
strategies to address my research question. Exploratory studies allow researchers to
understand an issue, a problem, or a phenomenon (Saunders et al., 2015). Qualitative
studies focus on phenomena based on ideas related to human knowledge, including an
objective to share knowledge and extend research data (Ward et al., 2018). Using a
qualitative method, the researcher can understand a phenomenon through a participant’s
perspective based on rich data and thick descriptions (Azungah, 2018; Barnham, 2015).
Using the qualitative approach, researchers can gain an understanding of reasons behind a
phenomenon using an open-ended, exploratory stance, instead of proving or disproving
hypotheses (Taguchi, 2018). A qualitative approach can be valuable in case of novel
questions in business where there is less data or where little or no theory exists to deduce
research hypothesis (Reinecke, Arnold, & Palazzo, 2016). Therefore, a qualitative
approach was an appropriate methodology for this study.
Developing generalizable rules and verification or falsification of hypotheses are
the focus of quantitative research methods (House, 2018). Researchers collect numerical
data in order to test theories or hypotheses using measurement of specific variables
(Saunders et al., 2015). The research problem and question of my study did not require
testing correlations, hypotheses, or existing theories using statistical analysis or
mathematical models. Therefore, a quantitative approach was not suitable for this study.
Researchers use mixed method research when their research question can be best
answered by an integrated qualitative and quantitative research than either of them alone
(House, 2018; Saunders et al., 2015). Challenges of mix method include the large amount

52
of time the study requires, size of samples, and quality of data and related interpretation
during analysis (House, 2018). Mixed method is complicated and is discouraged for
students (Fusch et al., 2018). Though a mixed method approach may have fit my research
problem, required sample size, large amount of time, and potential for discrepancies
during analysis were major deterrents.
Research Design
A research design is a plan to collect and analyze data in order to obtain answers
to the research question to maximize validity and efficiency (Palinkas et al., 2015). Case
study, ethnography, and phenomenology are the common qualitative research designs.
Research questions pertaining to the understanding of organizational processes can be
best addressed using a case study approach (McIntosh & Morse, 2015). The two main
purposes of case study are exploration and theory-building (Runfola, Perna, Baraldi, &
Gregori, 2017). A case study is used to identify what decisions that were made, why, and
how they were implemented which yielded certain results (Yin, 2018). Using a case study
strategy enables researchers to perform in-depth inquiry into a topic to generate insights
in a real-life context experiences (Saunders et al., 2015; Yin, 2018). A case study focuses
on how things are and how they behave (Dresch et al., 2015). Case study facilitates
collecting richer information pertaining to a phenomenon (Dasgupta, 2015).
Semistructured interviews can assist in ascertaining participants’ perspectives of their
experiences related to the study topic (McIntosh & Morse, 2015).
A researcher selects a case study design to explore a smaller sample using
multiple approaches to gather data (Dresch, Pacheco Lacerda, & Cauchick Miguel, 2015)
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and conducts investigation and builds theories where the phenomenon is newer or poorly
understood (Runfola et al., 2017). A case study design can be conducted on a single case
or multiple cases. A single case study design is appropriate when researching a unique
case (Dasgupta, 2015). Multiple case design allows researchers to build theories by
proving a strong base for cross case analysis (Yin, 2018). A single case study design was
deemed more appropriate to explore strategies used by some PV managers to implement
innovative solutions for automation.
Case studies are more common (Sovacool et al., 2018) and popular than the other
qualitative research designs like phenomenology and ethnography. Phenomenology is
concerned about a less known lived experience (Lewis, 2015), whereas a case study
focuses on a phenomenon to be studied in the environment it takes place (Tobi &
Kampen, 2017). Researchers conduct phenomenological studies to analyze lived
experiences. Because my study focused on strategies used for implementation of
automation solutions, and not on lived experience of an employee, phenomenology was
not an appropriate design. The purpose of ethnography is exploration of a phenomenon in
a cultural context (Lewis, 2015). Because cultural context was not critical for my study,
ethnography was not a suitable design.
Data saturation is an important aspect of qualitative case studies. Data saturation
is reached when no new information or themes are observed and the information can be
used to replicate the study, making it capable of generalization (Fusch & Ness, 2015;
Saunders et al., 2017). The depth and richness of data will determine the data saturation
and not solely the sample size of the population (Boddy, 2016; Fusch & Ness, 2015). I
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ensured I collected in-depth information and rich and thick descriptions and continued the
interview process until no new information was discovered. I used member checking as
recommended by Fusch and Ness (2015) to achieve data saturation.
Population and Sampling
The study population is the total number of people within the organization eligible
for sampling consideration in the interview study (Yin, 2018). To fit the purpose of the
study and collect relevant knowledge, researchers following qualitative approach use
specific criteria to purposively sample participants (Lewis, 2015; Sovacool et al., 2018).
The target population for this single case study consisted of PV systems managers who
were involved in successfully implementing innovative technology strategies to automate
AE case processing and employed in the selected pharmaceutical company in the Boston
area of Massachusetts, United States. The participants were willing to participate in this
study.
Because this study is set in a specific function within a pharmaceutical industry, a
purposive sampling design was used to select participants for this study. A purposive
sampling design is used when a particular phenomenon is studied in a specific context
(Tobi & Kampen, 2017; Yin, 2018). The participant sample must be representative of the
population (Boddy, 2016). The sampling technique did not yield a large and diverse
selection of participants from the PV function of a small pharmaceutical company.
Therefore, I invited four PV systems managers to participate in the study.
To decide the number of participants to be interviewed for this study, I followed
the principles of data saturation. Data saturation is reached when no new information or
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themes are observed and the information can be used to replicate the study, making it
capable of generalization (Fusch & Ness, 2015; Saunders et al., 2017). The number of
participants for a study is contingent on the population chosen (Saunders & Townsend,
2016). The depth and richness of data will determine the data saturation and not solely
the sample size of the population (Boddy, 2016; Fusch & Ness, 2015).
I interviewed four PV systems managers, selected using the purposive sampling
method. In their qualitative study, Palaya, Pearson, and Nash (2018) conducted eight
interviews since the authors could not find additional participants matching the
participation criteria. Morley (2020) recruited and interviewed four participants for her
study. Kawano (2017) interviewed two sets of three participants each for her qualitative
study. Since no standards for sample size exist for qualitative studies (Malterud, 2016),
sample size for qualitative studies are varied, driven by data saturation. Also, since my
study participation criteria did not yield many participants, I interviewed four PV systems
managers working in a single pharmaceutical company.
I obtained authorization from Walden University’s IRB using which, I obtained
consent from potential candidates to participate. Walden University’s approval number
for this study is 04-24-20-0972741 and it expires on April 23, 2021. I contacted the study
participants by phone or email requesting their participation in the study and their
response indicating their willingness to participate was documented. Quantitative
interviews provide rich descriptions of complex organizational realities and offer
ecological validity (Saunders & Townsend, 2016). The interview protocol and the
interview questions as shown in the appendix A were administered to the participants via
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telephonic interviews. I digitally audio recorded and transcribed the interviews to
facilitate reliability of the data. Reliability is also ensured through member checking,
which is the process of involving the participants in the interpretation of data to enhance
the credibility of the results (Birt, Scott, Cavers, Campbell, & Walter, 2016). The
participants were asked additional questions if needed to confirm accuracy and obtain any
additional information or potential correction of data (Birt et al., 2016; Morse, 2015).
Member checking follow-up interviews were originally planned to be conducted if
required, to assist with interpretation of the transcripts. However, analysis and
interpretation of the transcripts did not require follow-up interviews.
Ethical Research
All research, regardless of methodology and context, face various ethical issues
when focusing on human experience needs, actions, and beliefs (Islam, 2019). Methods
of access, informed consent, conflict of interest, research design, relationship with the
participants, and understanding of contextual risks contribute to ethical concerns
(Wallace & Sheldon, 2015). I used confidentiality procedures to protect the participants
and maintain their privacy by following the protocols defined in the Belmont report
(National Commission for the Protection of Human Subjects and Biomedical and
Behavioral Research, 1979). To ensure adherence to the ethical standards, I obtained
approval from Walden University’s IRB. Walden University’s approval number for this
study is 04-24-20-0972741 and it expires on April 23, 2021.
Consent is a combination of the form or document and communication with the
participants as a part of the conversation (Wall & Pentz, 2016). I used the consent form
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and held an informed consent conversation prior to the interview to ensure the
participants understood the key elements and their rights pertaining to informed consent
as a recommended best practice by Koyfman, Reddy, Hizlan, Leek, and Kodish (2016).
The consent process must include the privacy and confidentiality protection (Ennever,
Nabi, Bass, Huang, & Fogler, 2019). I provided a student participant invitation and
informed consent form to all participants and obtained their consent to participate prior to
data collection. The participants had the right to withdraw from the study at any point
before and during the interview process and were asked to communicate their withdrawal
via email or by refusing to answer the interview questions and exit at any time.
Participation in this study was voluntary and no incentives were offered.
I conducted telephonic interviews by following the interview protocol and
questions (Appendix A). I followed the same protocol to interview all participants. I
digitally recorded the interviews after obtaining consent from the participants. To protect
the rights of the participants, I will store the data collected as password-protected files on
a flash drive for 5 years. After 5 years, I will duly destroy the data collected including the
recording files and any documents. To ensure confidentiality, I did not use the
participants’ names, organization name, or any identifiable information as a best practice
recommended by Ennever et al. (2019) and instead, assigned codes such as P1 and P2 to
the participants to ensure participant privacy. This study was voluntary. There was no
payment for participation.
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Data Collection Instruments
The researcher is the primary data collection instrument performing the data
collection and analysis activities in qualitative research (Cypress, 2018; Houghton,
Murphy, Brooker, & Casey, 2016). Qualitative researchers must begin to be reflexive and
must consider the ethicality of their methodology (Thurairajah, 2019). As the researcher,
I conducted this qualitative single case study using interviews to gather information. I
served as the data collection instrument by enrolling participants and interviewing them
using open-ended questions and collecting and analyzing the data from the
semistructured interviews.
The interview protocol (Appendix A) was used to conduct interviews and collect
data. Using a protocol ensured that the important aspects of the research questions from
the literature review were included in the interview (Azungah, 2018). Interview questions
for data collection covered important concepts of interest, which as suggested by Yin
(2018), provided a direction for data analysis. The quality of the interview protocol
impacts the study (Zhu & Mostafavi, 2017). The interview protocol (Appendix A)
contained multiple sections including an introduction and the list of questions developed
from the important aspects of the research question. I started with explaining the
background and the objective of the study, included the confidentiality statements, and
reminded the participants about withdrawal as defined in the protocol.
Interviews are a primary source of data for qualitative case studies (Runfola et al.,
2017; Yin, 2018). I used semistructured interviews guided by the interview protocol to
collect data to explore strategies used by PV systems managers to implement innovative
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technology solutions for automation. I included multiple sources of data to determine
convergent or divergent findings (Reinecke et al., 2016). Multiple sources of data like
interviews, reflective journals, or documents promote study validity via triangulation
(Morse, 2015; Yin, 2018). I searched for publicly available information like
announcements or presentations and additionally requested the participants for
documents they will be willing to share after the interview. I called the participants on
their preferred phone number at an agreed time. I obtained participant consent to audio
record the interview. To ensure data accuracy and reliability, I initiated the member
checking process and triangulation. Member checking or participant validation is the
process where the participant is involved in the interpretation of the data and is asked
additional questions during and after the interview to confirm accuracy and obtain any
additional information or potential correction of data (Birt et al., 2016; Morse, 2015). I
shared my interpretations with the participants and requested approval or corrections as a
part of member checking process. All participants confirmed accuracy and one
participant responded with minor corrections. The final versions of the transcript and
interpretation was used for data analysis.
Data Collection Technique
To explore strategies that PV systems managers used to implement innovative
technology solutions for automation, I collected data directly from the PV systems
managers in the form of interviews and additional documents. Yin (2018) identified four
principles of data collection to ensure high-quality case studies: use multiple sources of
evidence, a case study database, maintain a chain of evidence, and exercise care using
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electronic sources of evidence. The primary data collection technique I used is telephonic
semistructured interviews guided by the interview protocol (Appendix A). In addition, I
reviewed any publicly available information or presentation and documentation shared by
the participants related to this study. Interviewing, field observations, and document
analysis are the primary methods of data collection in qualitative studies (Chenail, 2011).
I obtained approval from Walden University IRB prior to interviewing the participants.
Walden University’s approval number for this study is 04-24-20-0972741 and it expires
on April 23, 2021. To focus on a particular phenomenon, I used the purposive sampling
design recommended by Tobi and Kampen (2017) to identify participants. I called the
participants at a predetermined time to conduct interviews. I shared the informed consent
form, reviewed the content of the form, and requested an email response confirming
willingness to participate in the study. Upon receiving permission from the participants, I
audio recorded the interviews using the voice recorder application installed on my
Samsung mobile phone. To enable consistency, maintain order, and ensure the
participants understand their rights, I used the interview protocol as a guide (CastilloMontoya, 2016). The same interview protocol was used with all the identified
participants to ensure consistency. Since reflective journaling can be used to improve
critical thinking and problem solving (Taliaferro & Diesel, 2016), I captured notes and
used reflective journaling approach and made notes to gain insight into events described
by the participants.
The use of semistructured interview approach allows the researcher to ask openended questions (Yin, 2018) and facilitate open interaction with the participants so they
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can provide rich data and thick descriptions. Interviews can be targeted to focus on a
specific topic and well-informed interviewees can offer credible insights. However, as
noted by Yin (2018), interviews are subject to problems of bias, inaccurate articulation,
and poor recall. To mitigate the problems, I shared the interview questions ahead of the
interview so the participants could collate the information and formulate their responses.
I transcribed the recorded interviews, and the transcripts and the interpretations
were shared with the participants to confirm accuracy and enhance validity by achieving
data saturation. Data saturation is achieved when no new information or themes are
observed and the information can be used to replicate the study (Fusch & Ness, 2015;
Saunders et al., 2017). Data saturation is critical to establish study validity (Morse, 2015).
Member checking and follow-up member checking interviews can also assist in reaching
data saturation (Yin, 2018). I included my assumptions and bias identified in my
reflective journal during the transcription of the interviews, with the objective of
surfacing any additional questions or clarifications to pursue as a part of follow-up
interviews. During the transcribing and interpretation, I did not have any additional
follow-up questions. All participants confirmed accuracy and one participant responded
with minor corrections. I had originally planned on conducting member checking followup interviews or email correspondences and edit the transcripts and interpretations
accordingly until data saturation was achieved. However, I did not need to conduct any
follow-up interviews and I was able to achieve data saturation.
In addition to providing answers to interview questions, I requested participants
for any documentation to corroborate the data. Documents such as standard operating
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procedures, policies, and best practices can help discover underlying themes (Yin, 2018).
Documents are stable and can corroborate evidence from other sources (Yin, 2018). Yin
(2018) also added that document review could result in contradictory evidence and the
findings might not corroborate with collected data, which can result in further
investigation. I triangulated the analysis of the documents received from the participants
and those publicly available and the interview data. Triangulation is a process of
authenticating information using multiple sources of data or methods concerning the
same event to decrease bias and increase validity of the study (Fusch et al., 2018; Joslin
& Müller, 2016). By performing triangulation and member checking, I created an
advantage for myself as the researcher to attempt to reduce bias and enhance the validity
and reliability of this study.
Data Organization Technique
To achieve the objectives of this study and ensure I conduct a high-quality study,
the following information was collected for this study: audio recording of every
semistructured interview captured via mobile phone, notes and journal entries,
transcriptions of the interviews, informed consent, reflective journal, project documents
and presentations regarding the innovative technology implementation as shared by the
participants. I had requested the participants for any project documents, public
presentations, procedures, policies, and best practice documents, and internal
communications. I collected the aforementioned documents and files electronically and
will store in a password protected flash drive for 5 years. I had planned to convert any
hard copies into electronic format to be able to store them digitally, after which the hard
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copies will be returned to the participants or destroyed by shredding. However, I did not
receive any hard or paper copies. I used ATLAS.ti software to organize the collected data
and maintain a list of codes and keywords, including bias from my reflective journal to
compile, disassemble, reassemble, interpret, and conclude the findings. In addition, I
established a case study database as recommended by Yin (2018) to track all the data
collected and maintain a chain of evidence. To ensure confidentiality and protect the
participants from harm, I refrained from using the participants’ names as recommended
by Ennever et al. (2019) and Wall and Pentz (2016) and instead, assign codes such as P1
and P2 to ensure participant privacy. A few participants identified names of the
organization during the interview. To maintain participant privacy, I removed all
occurrences of their names or the organization names while transcribing. I labeled the
data collected from the participants per the assigned codes. All the collected data will be
stored for 5 years after the completion of the study and duly destroyed after.
Data Analysis
Organizing the collected data and identifying realistic meaning and drawing
conclusions is the purpose of performing data analysis (Bengtsson, 2016). To enhance the
validity and reliability of my study and ensure data saturation, I performed triangulation
and member checking. Triangulation is a process of authenticating information using
multiple sources of data or methods concerning the same events to decrease bias and
increase validity of the study (Fusch et al., 2018; Joslin & Müller, 2016). Methodical
triangulation involves multiple methods of data collection to view a phenomenon (Fusch
et al., 2018; Sovacool et al., 2018; Yin, 2018). I used methodical triangulation approach
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and triangulate the data I collected from the interviews, internal and publicly available
company and project documentation as evidence of strategies the PV systems managers
used to implement innovative technology solutions for automation. The constructs of the
TTF model and the research question assisted in focusing the data analysis on the themes
identified from the literature review.
Based on Yin’s (2018) recommended five-step data analysis, I used the ATLAS.ti
software to compile, disassemble, reassemble, interpret, and conclude the findings. I
transcribed the data. After confirmation of accuracy from the participants, I used the final
version of the transcripts and interpretation for data analysis. I performed content analysis
by identifying themes and patterns in ATLAS.ti. The objective of content analysis is to
systematically identify themes and patterns by coding of interview transcripts and
documentation (Sovacool et al., 2018). I had identified a list of codes from my literature
review as my initial set of codes for analysis. I also included my assumptions and biases
recorded in my reflective journal for coding in ATLAS.ti software for data analysis. This
process assisted in successfully performing bracketing and the researcher bias was
included while performing content analysis. ATLAS.ti software assisted in organizing the
collected data, maintaining a list of codes and keywords to maintain consistency
(Bengtsson, 2016; Yin, 2018), and identifying themes. I established a case study database
as recommended by Yin (2018) to track all the data collected and maintain a chain of
evidence.
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Reliability and Validity
Reliability
Researchers must be methodical in order to establish rigor and ensure reliability
of their findings. Reliability refers to replication or repeatability to achieve consistent
findings (Bengtsson, 2016; Yin, 2018). To ensure dependability, repeatability, and
consistency during data collection, I used an interview protocol with a set of interview
questions (Appendix A) and administered the same protocol to all the participants.
Reliability can be achieved by designing a well thought out, consistent research process
by promoting stability while coding and analyzing the data, and being transparent with
reporting (Saunders et al., 2015). Despite being an efficient way of collecting data,
interviews can be biased, which can affect the reliability of the study (Runfola et al.,
2017). An unreliable research will be invalid since errors or bias will affect the findings,
the analysis, and the interpretation (Saunders et al., 2015). Strategies to ensure reliability
included using a coding system, member checks, thick description, and triangulation
(Morse, 2015).
Validity
Validity refers to appropriateness of measures, accuracy of analysis, and
generalizability (Saunders et al., 2015) that truthfully and accurately describes the
phenomena (Bengtsson, 2016). Validity refers to the credibility, transferability, and
confirmability of the findings. A study is credible when the results presented with the
context are recognizable to people who share the experience, which refers to truthfulness
or the internal validity of the study (Hammarberg, Kirkman, & de Lacey, 2016).
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Transferability is the extent to which the study findings are useful to other people, which
is achieved by researchers being transparent (Connelly, 2016). Confirmability refers to
the degree to which a study is consistent and can be repeated (Connelly, 2016). Validity
is one of the prime concerns of researchers using qualitative methodology (Fusch et al.,
2018). The subjective nature of unstructured data collection poses a threat to validity
(Morse, 2015). To determine validity, Morse (2015) identified prolonged engagement,
peer review, negative case analysis, using a coding system, member checking,
triangulation, etc. Data saturation is important to establish validity and is reached when
there is enough information to replicate the study and there is no additional new
information (Fusch & Ness, 2015; Saunders et al., 2017).
I used two techniques to establish reliability and validity in this study: (a)
triangulation which is a process of authenticating information using multiple sources of
data or methods concerning the same phenomenon to decrease bias and increase validity
of the study (Fusch et al., 2018; Joslin & Müller, 2016). (b) member checking or
participant validation: the process where the participant in involved in the interpretation
of the collected data and is questioned during the interview process to confirm accuracy
and obtain any additional information or potential correction of data (Birt et al., 2016;
Morse, 2015). I used both triangulation and member checking as methods to reach data
saturation. Data saturation is reached when no new information or themes are observed
and the information can be used to replicate the study, making it capable of
generalization (Fusch & Ness, 2015; Saunders et al., 2017). Data saturation refers to the
depth of the data (Fusch & Ness, 2015). I ensured I collected in-depth information and
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rich and thick descriptions and continued the interview process until no new information
was discovered. I used member checking as recommended by Fusch and Ness (2015) to
achieve data saturation.
I gathered rich data and thick descriptions and documentation during the
interviews (Sovacool et al., 2018) to allow for transfer of the study findings to another
context, thereby increasing credibility. I shared the interview transcripts and my
interpretation with the participants to review and confirm the accuracy of the transcripts
and my interpretation of the events. To increase confirmability, I included my
assumptions and bias identified in my reflective journal during the transcription of the
interviews, with the intention of surfacing any additional questions or clarifications to
pursue as a part of follow-up interviews. I also included my assumptions and bias during
data analysis to perform bracketing and assist with mitigating bias. To ensure
confirmability and data saturation, member checking was conducted until no new
information emerged. However, I did not conduct follow up interviews. I triangulated the
information gathered from the interviews with the documentation to further confirm data
saturation. To increase the reliability of the study, I established a case study database as
recommended by Yin (2018) to track all the data collected and maintain a chain of
evidence. I addition, I maintained an audit trail and recorded the approach for the data
collection, interpretation, and analysis to enable retracing of the steps and duplication,
thereby increasing transferability.
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Transition and Summary
The purpose of this qualitative single study was to explore the strategies used by
PV systems managers to implement innovative technology solutions to automate AE case
processing. In section 2, I provided justification for selecting qualitative single case
design for this study and focused on the strategies and approaches used for key
components of this study. I explained the research method and design, population and
sampling of participants, my role as the research instrument, and my approach for ethical
research, data collection instruments and techniques, data organization techniques, data
analysis, reliability, and validity that were used for this study. Upon approval from the
IRB, I collected the data, performed data analysis, and then expanded this study to
include the data analysis and findings of this doctoral study. In the next section, I
describe the findings of the study, recommendations for future research, reflections, and
conclusion.

69
Section 3: Application to Professional Practice and Implications for Change
Introduction
The purpose of this qualitative single case study was to explore the strategies that
PV systems managers in the pharmaceutical industry use to implement innovative
technology solutions to automate AE case processing. I used a purposive sampling
technique to select four PV systems managers working in a pharmaceutical company
located in the Boston area of Massachusetts, United States, who have used successful
strategies to implement innovative automation technology solutions for AE case
processing. I collected data from semistructured interviews, conducted using an interview
protocol (Appendix A) until data saturation was reached, and triangulated the data with
documents collected from the participants.
Three themes with nine strategies emerged during data analysis. The themes were
(a) automation solution selection and implementation strategies, (b) business operational
model changes, and (c) communication and training strategies. Internal drivers like
vision, objectives, timelines, cost, and compliance; ensuring solution is fit for purpose;
open communication, collaboration, and engagement; strong project management; and
simplified, standardized, and efficient business processes emerged as the key strategies
from these themes. The organization had contracted an external vendor to build a
strategic long-term partnership for their PV database, which was their foremost selection
and implementation strategy. The findings supported the existing findings on strategies
from the academic literature review. In the next sections, I will present the study findings,
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application to professional practice, implications for social change, recommendations for
action, recommendations for further research, reflections, and conclusion.
Presentation of the Findings
In this study, I focused on the strategies that PV systems managers use to
implement innovative technology solutions to automate AE case processing. I conducted
semistructured interviews to collect data from four PV systems managers from a
pharmaceutical company in the Boston area of Massachusetts, United States. I used the
TTF model as the conceptual framework to guide my research on identifying the
strategies PV systems managers use for automating PV case processing.
Lai (2017) noted that the TTF model is suitable for investigating the utilization of
new technology solutions. Therefore, the constructs of the TTF model were used as the
conceptual lens to identify the strategies from the collected data. I used ATLAS.ti
software to organize and analyze the data collected from the interviews. I manually
analyzed the documents collected from the participants for document review. For initial
analysis, I used word cloud for a visual representation of word frequency to get the first
look and summarize the interview transcripts. The word cloud showed system, project,
vendor, automation, implementation, communication, change, issues, and users as the
key and most frequently used words by participants in the interviews as shown in Figure
4. The words mapped to the themes and strategies that were identified during detailed
analysis.
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Figure 4. Word cloud showing the most frequently used words in the interview data.
Created from ATLAS.ti.
The organization had contracted an external vendor to build a strategic long-term
partnership for their PV database, which was their foremost selection and implementation
strategy. The following key themes emerged with detailed analysis of the interview data:
(a) selection and implementation strategies, (b) business operational model changes, and
(c) communication and training strategies.
The automation solution selection and implementation strategies theme included
five key strategies: internal drivers like vision, objectives, timelines, cost, and
compliance; ensuring solution is fit for purpose; strong project management; strategic
partnership with an external vendor; and defined metrics to measure effectiveness of the
solution and project. Business operational model changes theme included two strategies:
Simplified, standardized, and efficient business processes by supplementing and reducing
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operational workforce and changes to organizational structure and job profiles.
Communication and training strategies included open communication, collaboration, and
engagement and training. The three main themes and the nine key strategies are shown in
Table 2 below. The references coded refers to the number of times the data references
were coded to the strategies.
Table 2
Themes and Strategies
Themes

Strategies

Selection and
implementation
strategies

Internal drivers like vision, objectives, timelines,
cost, and compliance

Business operational
model changes

Communication and
training strategies

References
coded
18

Ensure solution is fit for purpose

18

Strong project management with a defined plan,
dedicated resources, and stakeholders

16

Strategic partnership with an external vendor

14

Defined metrics to measure effectiveness of the
solution and project

7

Simplified, standardized, and efficient business
processes by supplementing and reducing
operational workforce

15

Changes to organizational structure and job
profiles

8

Open communication, collaboration, and
engagement with stakeholders incl. end users
and vendor

17

Training

5
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Theme 1: Selection and Implementation Strategies
Automation solution selection and implementation strategies was one of the key
themes that emerged from the interview data. I analyzed the data in two steps, initial and
detailed analysis. Initial analysis of the word cloud created by ATLAS.ti included vendor,
system, project, time, implementation, automation, and communication as the key words
as shown in Figure 5.

Figure 5. Word cloud for selection and implementation strategies in the interview data.
Created from ATLAS.ti.
The word cloud for automation solution selection and implementation strategies
reflected the strategies identified in the analysis of data. The leaders of the PV
organization decided to strategically engage with an external vendor to supply the
automation solution and implement the same. Managers have multiple options to
implement technologies and value propositions and adopt a leader or follower strategy in
the digitization arena (Ritter & Pedersen, 2019). This organization adopted the leader
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strategy for automation. P4 indicated that the company was the first to implement this
intake automation solution from the vendor. The following five key strategies emerged
for selection and implementation strategies from the interview data:
Internal drivers like vision, objectives, timelines, cost, and compliance. All
participants identified internal drivers as one of the important strategies to guide the
selection and implementation of automation solutions for AE case processing. The
participants identified multiple internal drivers or factors like organization vision and
objectives for automation, tight timelines, cost, and competing priorities while ensuring
regulatory compliance. P1 and P2 stated that the PV organization created a long-term
vision to leverage automation as much as possible to build efficiencies within PV
business operations. In addition, P2 stressed on selecting a vendor who had a long-term
vision and were invested in building and supporting the product. All participants
identified tight timeline and P1 and P3 listed cost and capabilities as key internal drivers
in addition. All participants stressed on staying compliant with regulations to process
AEs and building a validated, compliant system.
Ensure the solution is fit for purpose. All participants unanimously identified
the fit of the automation solution to effectively perform as expected and match the tasks
and constraints as a key strategy. P2 and P4 identified technical constraints like the
solution platform must be on the Cloud and be compatible with the newly implemented
PV database. Certain tasks which were performed manually were now replaced by a
tactical automated solution. Therefore, the solution must be a fit for the tasks that needed
to be performed, only more efficiently. Though the team had challenges with the solution
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functioning as expected initially, they overcame the issues by leveraging the partnership
with the vendor using collaboration and adjusting the business process and the solution to
find an acceptable compromise.
Strong project management with a defined plan, dedicated resources, and
stakeholders. The project team consisted of internal employees and the external vendor
team members. To successfully execute the project, a strong project management
function was led by an internal temporarily contracted project manager to track the
project and manage stakeholder engagement. To ensure the milestones and deliverables
were met as defined in the project plan, a structured project plan was built, and dedicated
resources and stakeholders were identified. All participants indicated strong project
management and leadership as a key strategy.
Strategic partnership with an external vendor. Because the automation
solution was sourced and implemented by an external vendor, the PV systems managers
decided to strike a strategic partnership with the vendor selected after a rigorous vetting
process. Participants shared the realization that being a small pharmaceutical company,
they did not have the relevant expertise inhouse. Therefore, PV management decided to
build a strategic partnership with an external vendor who can source the automation
solution and implement it. In addition, P2 stressed on partnering with a vendor with a
vision who was invested in the technology and the solution for a long term. P4
recommended having vendor support onsite during “go-live” though the vendor was
offshore and implementation project was executed remotely. Participants summarized
that a good partnership ensured the vendor was engaged and acted on any issue
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escalations.
Defined metrics to measure effectiveness of the solution and the project. The
PV leaders built multiple metrics to measure the effectiveness of both the automation
solution and the execution of the project. To ensure the solution was fit for purpose,
before and after metrics measuring the time and resources were built. All participants
indicated that the metrics measured the amount of time taken to create and process AEs
before and after the automation solution was implemented. To ensure the project matched
the internal drivers, the project was closely monitored to ensure all the milestones were
achieved.
Documents provided by the participants showed automation, business process
improvements, elimination of nonvalue-added activities, and metrics were the key
internal strategies of focus. The documents also indicated strong leadership, open
communication, and collaboration as key strategies for successfully implementing
automation solution for AE case processing. Technical limitations like multitenant cloud
implementation and adopting ISP configuration were included as internal drivers. The
document review revealed timeline as an internal driver, as mentioned by all the
participants in their interviews.
The findings matched the academic literature review. PV managers must create a
vision and project new technology as a product designed to create, attract, and satisfy
demand (Gherasim, 2011). Though many companies automate many steps in the PV
process, plenty of opportunities exist to make PV agile and efficient (Ghosh et al., 2020).
Organization leaders have realized that proactive external collaboration is beneficial for
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creation of new products and solutions (Di Fiore et al., 2017). Therefore, the PV
leadership decided to partner with an external vendor. PV managers must ensure the
technology solutions are aligned with the business needs and led by business operations
(Mishra et al., 2019). Managers must improve employees’ job satisfaction and solution
adoption by implementing IT solutions that fit the tasks and employees’ long-term
professional needs (Wang et al., 2020). Internal drivers of a company, specifically,
organizational culture and environmental issues must be considered to leverage
advantages of data analytics (Hawley, 2016). Automation can support human workforce
in managing the increasing AE volume, complexity, reporting timelines, and increasing
efficiency, consistency, and compliance (Routray et al., 2020). Companies typically
measure the benefits of automation in terms of quality, compliance, and efficiency
(Ghosh et al., 2020)
The TTF model links the task requirements, individual abilities, and the
functionality of technology (Goodhue & Thompson, 1995). TTF theory focuses on the
application and the general reliance on technologies and does not recommend any task or
technology pairings that could produce a strong effect (Howard & Rose, 2019). The
participants explained that the manual redundant tasks were identified first and then the
automation solution that matched the tasks and the constraints was selected to ensure that
the automation initiative was a success. Therefore, the TTF conceptual framework
provided the correct lens for exploring strategies used by the PV systems managers to
successfully automate AE case processing.
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Theme 2: Business Operational Model Changes
The second key theme that emerged from the data was business operational model
changes. This theme referred to the outcome of implementing the automation solution.
Initial analysis of the word cloud created by ATLAS.ti included AEs also called cases,
system, automation, change, implementation, and automatically as the key words as
shown in Figure 6.

Figure 6. Word cloud for business operational model changes in the interview data.
Created from ATLAS.ti.
Business operational model changes theme included the following two strategies:
Simplified, standardized, and efficient business processes by supplementing
and reducing operational workforce. All participants stated that the introduction of the
automation solution simplified and standardized the business processes and assisted in
building efficiencies, as intended. P1 and P2 noted that although reduction of workforce
was not the primary intention, the managers were able to successfully supplement the
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manual, redundant tasks like double data entry to free up and repurpose the workforce to
focus on more value-added tasks. P4 indicated that the PV operations team could reduce
the number of full-time employees.
Changes to organizational structure and job profiles. The introduction of
automation solution led to changes in the way the AE case processing employees
performed their jobs. P1 indicated that the AE case processor now only has to read the
data on the screen as opposed to having to type or enter it manually. P2 and P3 noted that
the mailbox that had to be monitored for new AEs need not be monitored because the
AEs were automatically created in the database and the task was eliminated.
Review of the documents provided by the participants showed process
improvements and elimination of nonvalue-added activities as key objectives for
automation. One of the challenges that the PV organization targeted to resolve was
manual, time consuming, and inefficient processes. Ever increasing AE case volume,
derivative operational cost, and resources were the other key challenges that the PV
leadership decided to mitigate.
The findings for business operational model changes matched previous studies in
this regard. Stergiopoulos et al. (2019) noted that all PV leaders believed implementing
AI-based solutions will decrease costs for PV operations including simplifying AE
detection and processing. Mishra et al. (2019) summarized that business process
simplification, standardization, and re-engineering are the critical factors for a successful
automation strategy. Routray et al. (2020) confirmed that human intervention and review
of AE seriousness will be required, and that automation can augment human review by
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increasing efficiencies and consistency, thereby enabling reporting compliance. Beninger
(2018) emphasized on the new skillsets, which will define the roles of the next generation
of professionals who perform PV activities. Tomita (2019) added that organizations must
expect to supplement the human workforce with expert systems.
The TTF model matches the tasks as the events occur with the ability of a
technology to address these events. TTF focuses on the application of technology
(Howard & Rose, 2019). As concluded by Wang et al. (2020), the results of this study
indicated that the automation technology implementation resulted in business process reengineering. The results also indicated that if the automation solution fits the business
processes to successfully complete the tasks and enables employees’ personal fulfillment
(Wang et al., 2020), then the managers can expect enhanced adoption of the technologies
from the employees and a favorable attitude toward their jobs.
Theme 3: Communication and Training Strategies
The third key theme that emerged from the data was communication and training
strategies. This theme included change management-related strategies. Initial analysis of
the word cloud created by ATLAS.ti included communication, vendor, training, project,
team, and management as the key words as shown in Figure 7.
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Figure 7. Word cloud for communication and training strategies in the interview data.
Created from ATLAS.ti.
Effective communication and training strategies played a key role in successful
change management and adoption of the innovative technology solution within the PV
organization. Communication and training strategies theme included the following two
strategies:
Open communication, collaboration, and engagement with stakeholders
including end users and the vendor. Considering the high priority and ranking of the
AE automation project, the project team maintained open communication and
collaboration channels to ensure all the relevant stakeholders stayed engaged throughout
the implementation. All participants indicated that communication was key and that
introducing automation was viewed as a welcome change for the AE processing
operational activities. P2 noted that the end users were made an integral part of the
project, which made change management effortless. Managing the vendor using open
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communication and collaboration was critical. Multiple touch points like steering
committee and core team meetings were built to ensure the information is flowing
through the organization and timely escalation and resolution of issues. P1 and P2 also
indicated collaborating externally with other companies to explore the opportunities for
automation, which can be practically implemented.
Training. Since the introduction of automation changed the way certain business
processes were managed, training was a critical aspect. The participants noted that
multiple cycles of training were provided to the end users and the impacted third-party
call center vendor. P2 and P3 explained that the end users were engaged in the
implementation project and were trained multiple times.
Review of the documents shared by the participants revealed that open
communication and collaboration were key to set up an optimum governance structure
during implementation. Lack of efficient collaboration tools was a key challenge in the
initial stages of the project. Considering varied stakeholders, both internal and external,
and the vendor implementation team located remotely added to the communication
challenges. The team used online collaboration tools like Google and Smart Sheets to
help track tasks and keep the teams aligned.
Findings regarding communication and training strategies matched previous
studies. Training and re-learning initiatives assist in preparing and guiding the in-house
staff for digital transformation (Mishra et al., 2019). The human and technology
relationship should also include user training, interaction, and collaboration sub-goals in
order to be effective (Oyekan et al., 2017). PV systems managers realized the importance
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of communication and collaboration early during the implementation project and ensured
adequate measures were included to create open communication channels assisting in
timely escalations and change management. Ghosh et al (2020) also recommended
collaboration across the pharmaceutical industry between regulators and companies to
build a generic process flow to fuel third-party innovations.
In the TTF model, Goodhue and Thompson (1995) linked the technology solution
with individual performance. Wang et al. (2020) used the user task technology fit model
to summarize that the technology solutions alter business processes and existing work
patterns leading to re-training and re-learning, which could increase employees’ workrelated stress (Wang et al., 2020). The study results showed that engaging the users early
during the technology implementation led to easier change management and enhanced
adoption of the solution and possibly job satisfaction, since the solution was fit for
purpose.
I included the researcher biases and assumptions that I had identified during data
analysis. My biases and assumptions were confirmed to be a practical reality. PV systems
managers I interviewed confirmed that they made the decisions to identify and implement
innovative technology solutions. Participant P1 confirmed that among the many strategies
available the PV organization managers decided to pursue the few above mentioned
strategies for successful implementation. All participants confirmed that PV business
operational model had an impact of introducing automation. And finally, the participants
confirmed that innovative automation technology was used by their organization to
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automatically read and create database entries, thereby eliminating redundant manual
tasks, improving efficiencies, and over a period, achieving cost savings at the same time.
Applications to Professional Practice
Processing of an AE is an expensive resource-intensive process, which includes
high risk of errors and operational inefficiencies (Ghosh et al., 2020). A detailed review
of literature concluded that innovative technology such as data mining, machine learning,
AI, and robotics could result in new operating models for PV (Beninger & Ibara, 2016;
Lai, 2017), improve efficiencies and reduce PV operations costs (Karimi et al., 2015; Lu,
2009; Schmider et al., 2018), better allocation of resources, and improve patient
outcomes (Lewis & McCallum, 2019). In this doctoral study, I explored the strategies
that PV systems managers in the pharmaceutical industry use to implement innovative
technology solutions to automate AE processing.
The single case that I selected to study was the implementation of an innovative
technology solution to automate AE processing. The organization had a larger vision to
automate PV business operations and this project was a part of that vision. Leaders and
managers in the PV function decided to partner with a vendor to source and implement
the solution, having realized that the organization lacked the necessary expertise on the
technology. Multiple internal drivers such as objectives, timelines, cost, and compliance
shaped the strategies the PV systems managers used to execute the project. Considering
this being their first automation solution, the team ensured that the solution is fit for
purpose, both task (functionality) and technology (architecture) perspectives. Strong
project leadership and steering committee were established for robust governance and
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monitoring. The managers established an open communication, collaboration, and
training model to engage with the relevant stakeholders across multiple functions within
the organization and the vendor. Measures were established to capture metrics in terms of
volume, time, and quality of the business AE processing tasks before and after
automation. Regular project governance and monitoring measures ensured the automation
solution was implemented on time. The metrics defined the successful outcome of this
implementation.
The results showed that implementing the automation solution impacted the PV
business operational model in a favorable manner. Business processes are now more
simplified, standardized, and efficient. The metrics revealed major savings in terms of
time and effort, which led to reduction in operational workforce and better allocation of
the resources. The organization has started reallocating the savings from the manual labor
toward more value-added tasks. By successfully implementing the automation solution,
the PV organization managers have started defining a sustainable model for PV business
operations. Other pharmaceutical companies can use the strategies identified in this study
to realize the benefits of implementing innovative automation technology solutions to
build a resilient and sustainable PV business operations organization.
Implications for Social Change
The successful strategies identified in this study can be used by organizations to
adopt a digitized PV future. The study findings show a positive outcome and realization
of savings from PV business operations because of strategically implementing and
embedding automation. PV leaders can redirect the savings from PV operations toward
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investing in the actual PV tasks like benefit-risk assessments of products, thereby
improving patient outcomes and making the products more efficacious and safer for
human use.
The challenges on the pharmaceutical industry’s perspective include the
management of the high volume of AEs, globally diverse and changing regulations,
complex and evolving systems, and sparse PV expertise and talent (Price, 2018).
Automation technologies can detect, database, and report AEs quicker, and manage high
volume of AEs, which can help in protecting patients from unnecessary harm. The
implications for positive social change include the identification of strategies to assist in
making pharmaceutical medicines safer for human consumption. The savings from PV
operations could also be used to help or assist with community projects that could bring
about social change. Companies can also use the savings to offer scholarships to students
pursuing courses and majoring in PV, thereby contributing to increase PV expertise and
talent.
Recommendations for Action
This study revealed multiple strategies used by PV managers to implement AE
case processing automation solution. The three themes that emerged included automation
solution selection and implementation strategies, business operational model changes,
and communication and training strategies. The results revealed that the PV systems
managers can follow their company’s internal processes for solution selection and
implementation, while paying close attention to the strategies identified in this study. By
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successfully implementing automation technology for AE case processing, PV managers
can realize time and effort savings and improve efficiencies with PV operations.
Other stakeholders in the pharmaceutical industry who could benefit from this
study include PV organization leaders and PV system database vendors. PV organization
leaders can include the strategies identified in this study as they start defining their PV
automation vision and objectives. PV system database vendors can build automation
solutions which fit the demand from the end users and build a mutually benefitting,
strategic partnership with the pharmaceutical industry. The findings of this study could
also provide valuable insights to researchers interested in further research in PV AE
management automation. I will share the findings of this study with the research
participants. Additionally, I will disseminate the results through scholarly journals.
Recommendations for Further Research
This qualitative study focused on a single case. I interviewed PV systems
managers employed in one pharmaceutical company. This study can be extended in a
future research to include additional perspectives like end user feedback and IT
technology strategies. Due to the ever-increasing volume of AE cases to be detected,
processed, and reported, more companies are building visions for digitalization and
sustainability by incorporating more automation for their PV business operations and
case management. This opens multiple avenues for future research. This study can be
replicated with other study population to explore additional successful strategies. This
study focused on successful strategies to implement automation and not on the actual
automation solution that was implemented. A future study can delve deeper into the
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technology that was used in addition to exploring successful implementation strategies.
One of the participants stated that their implementation was a success and that many
others are not. A future study can explore strategies that were unsuccessful, which can
serve as learnings for other companies starting on this journey.
Reflections
I work in the pharmaceutical industry and have extensive experience with
technology solutions and implementations. I selected this research topic based on an
exploration project I conducted for the company I work for as the PV leaders were
exploring the PV landscape with an automation lens. Since I was close to the topic, I had
assumptions and preconceived thoughts regarding automation solution implementation
strategies. Therefore, mitigating personal bias was crucial for my study. I made a list of
my potential bias and included them during data analysis. The results showed that my
biases and assumptions were practical realities.
The doctoral study process seemed a daunting task when I started. Soon, I started
enjoying the process of conceptualizing the research, conducting, and concluding it. I did
not face any challenges with the selection of participants and interviewing them. The
participants took pride in their successful implementation as they are seeing the benefits
now. I conducted my doctoral study as the small-scale project in the DBA Qualitative
Research process course. I could effectively use the learnings from the pilot run for my
study.
I decided to use innovative technology as a part of the study data analysis process.
I used an application on my mobile phone for the initial transcript of the interviews. The

89
application audio recorded the interview and converted it into a transcript output, which
saved many hours of transcribing effort. I proof-read the entire output, paraphrased as
needed, and subjected it to member checking process for confirming accuracy.
Conclusion
Processing of an AE is an expensive resource-intensive process, which includes
high risk of errors and operational inefficiencies (Ghosh et al., 2020). As deducted in
multiple previous research, technology can accelerate efficiencies and can be used to
identify and process AEs faster and contribute to reduction of costs (Beninger, 2018;
Donzanti, 2018; Karimi et al., 2015; Kusch et al., 2020; Lewis & McCullum, 2019;
Schmider et al., 2018; Stergiopoulos et al., 2019). Organizations must internalize
digitalization and incorporate in the operations methodology and structure in order to
select the most suitable technological solutions and reap the maximum benefits
(Buyukozkan & Gocer, 2018). Many pharmaceutical organizations are experimenting,
and some are implementing automation technology solutions for AE case processing.
This study focused on one such company whose PV organization managers have
implemented an automation solution for AE case processing. The results of the study are
in line with previous research. By prudently executing automation solution selection and
implementation strategies and establishing communication and training strategies, the
organization is now benefitting from simplified and efficient AE case processing business
operations. Multiple factors such as internal drivers like cost and timelines, functionality
of the automation solution, strong project leadership, stakeholder partnerships and
engagement, including the size of the organization play an important role in shaping the
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outcome of the digitalization initiative. With careful planning and execution, intelligent
AE case processing automation initiative can be a success and be sustained over the long
term.
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Appendix A: Interview Protocol
Interview introduction:
1. Introduce the topic and objectives.
2. Explain the purpose and scope of the study.
3. Assure participants that their name and organization information will be
kept confidential.
4. Ask to record the interview and let the participant know that the materials
will be stored for a maximum of 5 years.
5. Let participants know they can stop if they do not wish to proceed.
Strategic research
questions

1. What strategies did you use to identify automation
solutions for AE case processing?
2. What strategies did you use for implementing the

Reminders to do during
the interview:

identified automation solution?
3. What, if any, kinds of operational changes did the

Watch for nonverbal cues.

automation solution require to your PV business

Paraphrase as needed.

operations model?

Ask follow-up probing

4. What communication strategies were used to

questions to get more in-

manage regulatory obligations and employee’s

depth, rich data.

expectations to enable employee’s adoption of the
automation solution?
5. What key difficulties did your organization face
when implementing the automation technology
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solution?
6. How did your organization overcome the key
difficulties to implementing automation technology
solution?
7. How did your organization assess the
implementation strategies’ effectiveness?
8. What additional information can you add about the
development and implementation of the strategies
your organization used for automating AE case
processing?

Wrap up interview

Thank the participant for their time and information.
Schedule a follow-up interview for member checking.

Follow-up member
checking interview

Reminders to do during

Introduction:
1.

Reiterate and refresh the topic and objectives.

2.

Introduction for follow-up.

3.

Assure participants that their name and organization

the interview:

information will be kept confidential.

Watch for nonverbal cues.

4.

Ask to record the follow-up interview.

Paraphrase as needed.

5.

Let participants know they can stop if they do not

Ask follow-up probing
questions to get more in-

wish to proceed.
Follow-up Interview:
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depth, rich data.

1.

Share a copy of the interpretation and synthesis of
answers for each question.

2.

Walk through each question including the
interpretation of answers to ensure information was
not missed and include any additional information.

3.

Ask any additional questions related to the initial
interview to add clarity to the research topic.

4.

Wrap up follow-up interview by thanking the
participant.

